吉野　孝之（Takayuki Yoshino）MD, PhD

- **学校法人　慶應義塾大学　医学部　国際先端医療研究開発センター教授**
- **国立研究開発法人　国立がん研究センター東病院　東病院長特任補佐・国際臨床腫瘍科長・消化管内科医長**
- **一般社団法人　日本癌治療学会　理事長**
- **公益社団法人　日本臨床腫瘍学会　理事長**
- **学校法人　近畿大学医学部　特別招聘研究教授**
- **国立大学法人　筑波大学医学医療系教授（連携大学院）**

1989-1995　防衛医科大学校

1995-1997　防衛医科大学校病院　研修医

1997-1999　国立がんセンター中央病院　臨床検査部・病理部　研修医

1999-2001　国立がんセンター東病院　内視鏡部消化器内科　研修医

2001-2002　国立がんセンター東病院　内視鏡部消化器内科　非常勤医師

2002-2007.7 静岡県立静岡がんセンター　消化器内科　副医長

2007.8-2010.3 国立がんセンター東病院　内視鏡部消化器内科　医員

2010.4-2014.10 国立がん研究センター東病院　消化管内科　外来・病棟医長

2016.3-2020.3 国立がん研究センター東病院　治験管理室室長　併任

2013.4-2021.4 国立がん研究センター　先端医療開発センタートランスレーショナルリサーチ分野　併任

2014.11-2022.12 国立がん研究センター東病院　消化管内科　科長

2017.1-2021.8 国立がん研究センター東病院　臨床研究支援部門・研究実施管理部長　併任

2021.5—2022.4 国立がん研究センター東病院　臨床研究支援部門・トランスレーショナルリサーチ推進部長

2021.6-2022.4 国立がん研究センター東病院　データサイエンス部長代行

2022.5-2023.3 国立がん研究センター東病院　データサイエンス部長

2022.4-2025.3 国立がん研究センター東病院　副院長（研究担当）

2022.5-現在　国立がん研究センター東病院　医薬品開発推進部門長

2023.1-現在 国立がん研究センター東病院　消化管内科　医長

2023.4-2026.3 国立大学法人 東海国立大学機構 岐阜大学 大学院医学系研究科 特任教授

2023.10-現在 一般社団法人 日本癌治療学会 理事長

2024.4-現在 学校法人 近畿大学医学部 特別招聘研究教授

2024.12-現在 国立大学法人 筑波大学医学医療系教授（連携大学院）

2025.4-2026.5 慶應義塾大学医学部 がんゲノム医療センター 特任教授

2025.4-現在　国立がん研究センター東病院　国際臨床腫瘍科　科長

2025.4-2026.5 国立がん研究センター東病院　副院長（経営担当）

2026.3-現在　公益社団法人　日本臨床腫瘍学会　理事長

2026.6-現在　慶應義塾大学医学部 国際先端医療研究開発センター教授
2026.6-現在　国立がん研究センター東病院　病院長特任補佐

海外留学：2005 Mayo Clinic, college of medicine, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute

専門分野：消化管がん薬物療法の新薬開発、クリニカルシーケンスによるがん治療最適化と新規バイオマーカーの探索

医学博士：2017 年 7 月 19 日　香川大学

賞罰等
Jpn J Clin Oncol Paper of the Year 2013
BEST DOCTORS IN JAPAN 2020
ASCO2022 Annual Meeting Plenary Session Speaker（2022 年 6 月 5 日）
第 20 回 SGH 特別賞（旧佐川特別研究助成賞）受賞　2022 年 12 月 3 日
第 18 回小林がん学術賞　受賞　2024 年 6 月 15 日
第 14 回 JCA-永山賞（旧 JCA-CHAAO 賞）　受賞　2024 年 9 月 21 日
Highly Cited Researcher Awards 2024（高被引用論文著者）by Clarivate　2024 年 11 月 19 日
第 54 回高松宮妃癌研究基金 学術賞　受賞　2025 年 2 月 21 日

Contribution to the Scholar Journals
Editorial Board member of *Annals of Oncology*
Associate Editor of *Therapeutic Advances in Medical Oncology*
Associate Editor of *Clinical Colorectal Cancer*
Editorial Board member of *International Journal of Clinical Oncology*
Reviewer of *the Lancet Oncology*
The Lancet Oncology international advisory board

所属・委員会：

- ASCO（American Society of Clinical Oncology）active member, Editorial Board of ESMO/ASCO Global Curriculum, ASCO Breakthrough 2023 Advisory Committee Member, ASCO Breakthrough 2024 Co-Host Committee Member, ASCO-GI 2022 Faculty, ASCO Annual Meeting Scientific Program Committee on the Gastrointestinal Cancer-Colorectal and Anal Track（June 5, 2024 to June 4, 2027）
- ESMO（European Society for Medical Oncology）active member、大腸癌ガイドライン作成委員、

Pan-Asia 大腸癌ガイドライン委員長、Pan-Asia ガイドラインプロジェクト国際コーディネーター, Editorial Board of ESMO/ASCO Global Curriculum, ESMO Guidelines Steering Committee, ESMO Precision Medicine Working Group Member

- AACR（American Association for Cancer Research）active member, Scientific Program Committee Member 2022
- AOS（Asian Oncology Society）Secretary General（2023-）
- 日本臨床腫瘍学会　理事長（2026-）、理事（2019-2024）、将来構想委員会委員長（2026-）、指名委員会委員長（2026-）、賞等選考委員会委員長（2026-）、教育企画部会長（2019-2021）、国際委員会委員長（2022-2024）、評議員
- 日本癌治療学会　理事長(2023-)、副理事長(2021-2023)、理事(2019-)、将来計画委員会委員長(2023-)、広報・渉外委員会委員長（2021-2023）、総務委員会委員長（2019-2021）、国際委員会副委員長（2019-2023）、学会事務局長（2019-2021）、代議員
- 日本医学会　評議員
- 日本がん治療認定医機構　副理事長（2025-）理事（2024-）
- 日本がん分子標的治療学会　理事（2017-2022）、評議員
- 日本癌学会　評議員
- 大腸癌研究会　ガイドライン作成アドバイザー
- DIA諮問委員会委員
- JCOG運営委員会委員
- 日本内科学会・日本消化器病学会
- 大阪医科大学　非常勤講師
- 国立大学法人九州大学　先導物質化学研究所　客員教授（2022. 10-12）
- 国立大学法人東海国立大学機構岐阜大学大学院医学系研究科・特任教授（2023.4-2026.3）
- 一般社団法人　がん医療創生機構　理事（2024.3-）
- 学校法人　近畿大学医学部　特別招聘研究教授（2024.4-）
- がん対策推進協議会　委員

- 平成 28 年度国立がん研究センター研究開発費 28-A-5「がんゲノム情報を用いた全国レベルでの precision medicine 体制構築に関する研究」 主任研究者
- 平成 28 年度 AMED「産学連携全国がんゲノムスクリーニング事業 SCRUM-Japan で組織した遺伝子スクリーニング基盤を利用した、多施設多職種専門家から構成された Expert Panel による全国共通遺伝子解析・診断システムの構築および研修プログラムの開発」 主任研究者
- 平成 28 年度「臨床研究・治験推進研究事業（2 次公募）」産学連携全国がんゲノムスクリーニング（SCRUM-Japan）患者レジストリを活用した HER2 陽性の切除不能・再発大腸がんを対象にした医師主導治験　主任研究者
- 平成 29 年度 AMED「産学連携全国がんゲノムスクリーニング（SCRUM-Japan）患者レジストリを活用した *BRAF* 遺伝子変異陽性切除不能進行・再発大腸がんを対象にした医師主導治験」主任研究者
- 平成 30 年度 AMED「SCRUM-Japan の基盤を活用した血液循環腫瘍 DNA スクリーニングに基づく FGFR 遺伝子異常を有する難治性の治癒切除不能な進行・再発固形がんに対する TAS-120 のバスケット型医師主導治験」主任研究者

- 令和元年度厚生労働科学研究費補助金（がん対策推進総合研究事業）研究課題名：がんゲノム医療に携わる医師等の育成に資する研究　吉野小班長
- 令和元年度国立がん研究センター研究開発費 31-A-5「新たな解析技術を組み入れた国際的遺伝子スクリーニング基盤の構築と臨床開発に関する研究（31-A-5）」（NCC 大津班吉野小班）小班長
- 令和 3 年度国立がん研究センター研究開発費 2021-A-6「全エキソーム・ゲノム、マルチオミックス解析の臨床応用基盤構築及び人材育成に関する研究（2021-A-6）」（NCC 吉野班）班長
- 令和 3 年度 AMED「SCRUM-Japan の基盤を活用した血液循環腫瘍 DNA スクリーニングに基づく FGFR 遺伝子異常を有する難治性の治癒切除不能な進行・再発固形がんに対する TAS-120 のバスケット型医師主導治験」主任研究者
- 令和 5 年度 AMED 「人工知能を用いたリキッドバイオプシーマルチオミックスによる分子残存病変検出およびがん早期発見法の開発」主任研究者
- 令和 6 年度国立がん研究センター研究開発費 2024-A-04「進行固形がんおよび造血器悪性腫瘍における新しい解析法を含むマルチオミックス解析に基づいたがん個別化治療開発基盤の構築および運用に資する研究（2024-A-04）」（NCC 吉野班）班長
- 令和 8 年度 AMED 「血中循環腫瘍 DNA 陽性の治癒切除後結腸・直腸がん患者を対象とした S-531011 単独療法と S-531011＋ペムブロリズマブの有効性および安全性を評価する無作為化第 II 相試験」主任研究者

その他：

- 産学連携全国がんゲノムスクリーニング事業 SCRUM-Japan GI-SCREEN 主任研究者（2015 年 2 月～）
- CIRCULATE-Japan Project プログラム・ディレクター（2020 年 4 月～）
- ACCENT (Adjuvant Colon Cancer Endpoints Group) Steering Committee（2018 年 1 月～）
- Foundation ARCAD Advanced Colorectal Cancer Database 主任研究者（2020 年 2 月～）
- 一般社団法人 22 世紀先端医療情報機構　理事長
- ICGC-ARGO (International Cancer Genome Consortium - Accelerating Research in Genomic Oncology), Deputy Director, Executive Board Member, a chair of the Clinical and Metadata WG (formerly Tissue and Clinical Annotation WG).

最近の代表論文（2011 年以降）

1. Zheng-Lin B, Shibuki T, Kosiorek HE, Abidoye O, Eslinger CR, Kawamoto Y, Ramaker RC, Itoh S, Hashimoto T, Fujisawa T, Imai M, Pirozzi A, Hoyek C, Sonbol MB, Wu C, Tran NH, Babiker H, Roberts LR, Moyer AN, Nakamura Y, Bando H, **Yoshino T**, Ueno M, Morizane C, Ahn DH, Gottam M, Borad MJ, Strickler JH, Ikeda M, Bekaii-Saab T. Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis. ***NPJ Precis Oncol.*** 2026 May 5. doi: 10.1038/s41698-026-01457-3. Epub ahead of print. PMID: 42086664.
2. Kataoka K, Kimura K, Imada A, Ito K, Rao Z, Fukumoto Y, Song J, Horio Y, Kuwahara R, Uchino M, **Yoshino T**, Oki E, Kanemitsu Y, Ikeda M. Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases. ***Cancers (Basel).*** 2026 Apr 8;18(8):1188. doi: 10.3390/cancers18081188. PMID: 42073513.
3. Oyoshi H, Bando H, Yamashita R, Kageyama SI, Nakamura Y, Horasawa S, Nakamura M, Fujisawa T, Tomizawa K, Motegi A, Hojo H, Hirata H, Yukami H, Mishima S, Kotani D, Miyo M, Ando K, Watanabe J, Akazawa N, Kataoka K, Taniguchi H, Oki E, Takemasa I, Kato T, Mori M, Jurdi A, Liu MC, Misumi T, Zenda S, **Yoshino T**. Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection. ***NPJ Precis Oncol.*** 2026 Apr 30. doi: 10.1038/s41698-026-01450-w. Epub ahead of print. PMID: 42062528. **(*Senior author)***
4. Chi S, Motoike IN, Fujisawa T, Yamaguchi-Kabata Y, Nobukuni T, Kinoshita K, Nakamura Y, Bando H, **Yoshino T**, Ohneda K, Tsuchihara K, Minami Y, Yamashita R. Population-Based Identification of Clonal Hematopoiesis Using Peripheral Blood Whole-Genome Sequencing in Japan. ***Cancer Sci.*** 2026 Apr 29. doi: 10.1111/cas.70406. Epub ahead of print. PMID: 42053152.
5. Imai M, Yamashita R, Fujisawa T, Sokuoka H, Miki I, Sakamoto Y, Misumi T, Zandkarimi B, Ernst PT, Bando H, **Yoshino T**. The Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncology. ***Nat Med.*** 2026 Apr 21. doi: 10.1038/s41591-026-04346-1. Epub ahead of print. PMID: 42014508. **(*Senior & Corresponding author)***
6. Ebata Y, Oki E, Hu Q, Hasuda H, Kawazoe T, Nambara S, Tsuda Y, Nakanoko T, Ando K, Kimura Y, Sawada K, Yamashita R, Horasawa S, Fujisawa T, Bando H, Nakamura Y, **Yoshino T**, Yokota H, Ohno H, Yoshizumi T. Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response. ***Esophagus***. 2026 Apr 20. doi: 10.1007/s10388-026-01205-3. Epub ahead of print. PMID: 42008212.
7. Okemoto D, Nakayama I, Jubashi A, Sakamoto N, Okunaka M, Matsubara Y, Miyashita

Y, Kobayashi A, Okazaki U, Yamamoto K, Seguchi K, Hosokai T, Ogura T, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Kuwata T, Yamaguchi T, Nishikawa H, Shitara K. Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer. ***ESMO Gastrointest Oncol.*** 2026 Jan 27;11:100300. doi: 10.1016/j.esmogo.2025.100300. PMID: 41994003; PMCID: PMC13080937.

8. Cremolini C, Chalabi M, Elez E, Fassan M, Gelli M, Goéré D, Modest DP, Montagut C, Osterlund P, Ricke J, Seligmann J, Taieb J, **Yoshino T**, Wyrwicz L, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ***Ann Oncol.*** 2026 Dec 31:S0923-7534(26)00108-0. doi: 10.1016/j.annonc.2026.03.005. Epub ahead of print. PMID: 41990853.
9. Yajima S, Tsukada Y, Yamashita R, Fujisawa T, Kuwata T, Watanabe R, Ishii G, Gabelia N, Juhl H, Koga Y, **Yoshino T**, Ito M, Masuda H. Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion. ***Cancer Med.*** 2026 Apr;15(4):e71843. doi: 10.1002/cam4.71843. PMID: 41981779.
10. Ando K, Hamabe A, Nakamura Y, Watanabe J, Hirata K, Kataoka K, Miyo M, Kato K, Akazawa N, Kagawa Y, Yokota M, Yamazaki K, Mishima S, Yukami H, Kotani D, Bando H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Taniguchi H, Takemasa I, Kato T, **Yoshino T**, Oki E. Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery A Prospective Cohort Study: Erratum. ***Ann Surg.*** 2026 May 1;283(5):e7. doi: 10.1097/SLA.0000000000007009. Epub 2026 Apr 9. PMID: 41952206.
11. Walden D, Batalini F, Eslinger C, Nakamura Y, Krueger A, Deshmukh SK, Yamanaka K, Wu C, Sonbol MB, Wu S, Xiu J, Strickler J, Borad MJ, Ahn D, Muro K, **Yoshino T**, Bekaii-Saab T. Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer. ***JCO Precis Oncol.*** 2026 Apr;10(4):e2500452. doi: 10.1200/PO-25-00452. Epub 2026 Apr 3. PMID: 41931743.
12. Duan Y, Hashimoto T, Shibuki T, Taniguchi H, Sunakawa Y, Komatsu Y, Takahashi N, Sato Y, Yamaguchi K, Nishina T, Nakanoko T, Boku S, Satoh T, Yasui H, Esaki T, Imai M, Fujisawa T, Nakamura Y, Bando H, **Yoshino T**. Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy. ***JCO Precis Oncol.*** 2026 Mar;10(3):e2500971. doi: 10.1200/PO-25-00971. Epub 2026

Mar 30. PMID: 41911515. **(*Senior author)***

13. Shibuki T, Yamashita R, Hashimoto T, Fujisawa T, Imai M, Yuda J, Kuwata T, Misumi T, Nakamura Y, Bando H, Kojima K, Tokioka S, Chiba I, Nakaya N, Hozawa A, Koshiba S, Fuse N, Saito S, Shimizu R, Park WY, Kinoshita K, **Yoshino T**. Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI). ***Int J Clin Oncol.*** 2026 Mar 6. doi: 10.1007/s10147-026-03001-6. Epub ahead of print. PMID: 41790338. **(*Senior author)***
14. Iwabuchi S, Sawada K, Kojima M, Ozawa M, Taniguchi H, Bando H, Abe K, Kuze Y, Imamura K, Kashima Y, Hirohashi Y, Tajima A, Torigoe T, Suzuki Y, **Yoshino T**, Hashimoto S. Single-Cell Analysis Identified a Recurrent Malignant-Associated Transcriptional State in Colorectal Cancer. ***Cancer Sci.*** 2026 Mar 2. doi: 10.1111/cas.70335. Epub ahead of print. PMID: 41770629.
15. Kimura K, Kuwata T, Hiraoka Y, Matsukawa M, Tomozawa C, Aitani M, Komura Y, Miki I, Wakabayashi M, Furui Y, Kondo H, Saigoh K, Yamamoto Y, Akagi K, Narimatsu H, Yokono M, Amano S, Muto K, Nagami F, Kato K, Yamashita R, Imoto I, Kosugi S, Hirata M, **Yoshino T**, Nakamura Y. Psychological distress and cancer worry in unaffected relatives undergoing cascade testing with multigene panel testing. ***J Hum Genet.*** 2026 Mar 2. doi: 10.1038/s10038-026-01464-z. Epub ahead of print. PMID: 41765989.
16. Yamamoto K, Nakayama I, Sakamoto N, Matsubara Y, Miyashita Y, Kobayashi A, Okazaki U, Okemoto D, Seguchi K, Hosokai T, Ogura T, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Kuwata T, Shitara K. Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer. ***ESMO Gastrointest Oncol.*** 2025 Jul 17;9:100206. doi: 10.1016/j.esmogo.2025.100206. PMID: 41647968; PMCID: PMC12836749.
17. Nagamine M, Fujisawa T, Sakamoto N, Nakamura Y, Kadowaki S, Ueno M, Boku S, Komatsu Y, Oki E, Makiyama A, Nonomura N, Morizane C, Watari H, Okano S, Iwata H, Namikawa K, Hatanaka Y, Hatanaka KC, Taguchi K, Spetzler D, Radovich M, Magee D, **Yoshino T**, Oberley M, Kuwata T. HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry. ***JCO Precis Oncol.*** 2026 Jan;10:e2500413. doi: 10.1200/PO-25-00413. Epub 2026 Jan 21. PMID: 41564373.
18. Nakamura Y, Reiter JG, Natarajan P, Babiarz J, Srinivasan P, Joshi J, Lin Y, Chen TC, Liang N, Maw S, Haghshenas E, Kushwaha G, Gutman B, Tunc I, Chan WC, Tin A, Huang Y, Bristow SL, Malhotra M, Sharma S, Sanchez SA, Jurdi A, Liu MC, Kawli T, Rabinowitz M, Aleshin A, Kotani D, Eiji O, **Yoshino T**. Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study. ***NPJ***

Precis Oncol. 2026 Jan 19. doi: 10.1038/s41698-026-01277-5. Epub ahead of print. PMID: 41555007. **(*Senior & Corresponding author)***

19. Bando H, **Yoshino T**. STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer. ***Med.*** 2026 Jan 9;7(1):100957. doi: 10.1016/j.medj.2025.100957. PMID: 41519113. ***(Senior & Corresponding author)***
20. Suzuki K, Miyake H, Inaki A, Takano S, Kuboki Y, Mizowaki T, Nakamura K, Ueno M, Matsumoto S, Obinata D, Nakagawa T, Murakami M, Majima Y, Yokono M, Namba M, **Yoshino T**. Correction to: Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology. ***Int J Clin Oncol.*** 2026 Jan 8. doi: 10.1007/s10147-025-02925-9. Epub ahead of print. Erratum for: Int J Clin Oncol. 2025 Nov;30(11):2168-2177. doi: 10.1007/s10147-025-02858-3. PMID: 41504992. ***(Senior author)***

21. Boku S, Fujisawa T, Kadowaki S, Satake H, Yasui H, Ohtsubo K, Shimizu Y, Otsuka T, Kuze B, Yamashita R, Shibuki T, Nakamura Y, Bando H, **Yoshino T**, Radovich M, Okano S. Resistance mechanism to pembrolizumab in *DEK-AFF2* fusion-associated sinonasal squamous cell carcinoma. ***Int Cancer Conf J.*** 2025 Aug 20;14(4):458-463. doi: 10.1007/s13691-025-00796-5. PMID: 41395570; PMCID: PMC12696202.
22. Matsubara Y, Bando H, Nakamura Y, Misumi T, Ng D, Tajima E, Pittell H, Ohtsu A, **Yoshino T.** Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy. ***Br J Cancer.*** 2025 Dec 8. doi: 10.1038/s41416-025-03270-4. Epub ahead of print. PMID: 41361014. **(*Senior author)***
23. Pyun WY, Park JH, Roh JW, Jeon D, Kim J, Paik JE, Cho SC, Park SY, Lim H, Kim H, Jang YJ, Lee J, Byun JH, Son DW, Kim SY, Guan KL, Lee WD, Gee HY, Lee HW, No KT, Choi YS, Hashimoto T, **Yoshino T**, Jeong HS, Namkung W, Nam JH, Park HW. Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Non-oncology Drugs. ***Cancer Res.*** 2025 Nov 25. doi: 10.1158/0008-5472.CAN-25-1123. Epub ahead of print. PMID: 41289560.
24. Kamiya H, Kobayashi S, Kudo M, Sugimoto M, Kawazoe A, Bando H, Tsukada Y, Ito M, **Yoshino T**, Gotohda N. Prognostic stratification of recurrent colorectal liver metastasis: impact of recurrence-free interval, tumor numbers, and size on repeat liver resection. ***Int J Clin Oncol.*** 2025 Nov 21. doi: 10.1007/s10147-025-02921-z. Epub ahead of print. PMID: 41269485.
25. Osawa T, Matsubara N, Kato T, Shiota M, Nishimoto K, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Abutani H, Oda T, Fujisawa T, Nakamura Y, Sivakumar S, Eto M,

Yoshino T, Nonomura N. Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project. ***NPJ Precis Oncol.*** 2025 Nov 18;9(1):362. doi: 10.1038/s41698-025-01154-7. PMID: 41254099.

26. Hashimoto T, Iida N, Kadowaki S, Makiyama A, Machida N, Takahashi N, Boku S, Kudo T, Oki E, Ohtsubo K, Kawakami T, Okano N, Komatsu Y, Yuki S, Sakamoto N, Kuwata T, Yamashita R, Amisaki M, Shibuki T, Imai M, Fujisawa T, Nakamura Y, Bando H, Shitara K, **Yoshino T**. FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer. ***ESMO Open.*** 2025 Oct 30;10(11):105851. doi: 10.1016/j.esmoop.2025.105851. Epub ahead of print. PMID: 41172570. (***Senior author***)
27. Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Sunakawa Y, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Sakamoto Y, Kuramoto N, Miki I, Ichiki H, Nakamura Y, Sharma G, Skrzypczak S, Schultz E, Kingsford C, Ohtsu A, **Yoshino T**. A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701). ***ESMO Open.*** 2025 Oct 9;10(11):105839. doi: 10.1016/j.esmoop.2025.105839. Epub ahead of print. PMID: 41072075. ***(Senior Author)***
28. Tai D, Conroy T, Lee JJX, Chee CE, Hao CY, Wijaya I, Aggarwal S, Ueno M, Jeung HC, Hashim NM, Tan Chun Bing J, Chen LT, Korphaisarn K, Tanasanvimon S, Chou WC, Cargullo E, Muin NFA, Lee MA, Ohba A, Bondarde S, Lesmana CRA, Wang L, Smyth EC, **Yoshino T**, Bonney G, Pentheroudakis G, Samol J, Cervantes A, Poon E, Ducreux M. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. ***ESMO Open.*** 2025 Oct 8;10(10):105826. doi: 10.1016/j.esmoop.2025.105826. Epub ahead of print. PMID: 41067164.
29. Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Heinemann V, Cremolini C, Randolph Hecht J, Schmoll HJ, Nakayama G, Lenz HJ, Andre T, Shi Q, de Gramont A, Shitara K, **Yoshino T**. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. ***Eur J Cancer.*** 2025 Oct 2;230:116034. doi: 10.1016/j.ejca.2025.116034. Epub ahead of print. PMID: 41056789. **(*Senior & Corresponding author)***
30. Pastorino A, Liu H, Pederson L, Martelli V, Iveson T, de Gramont A, Alberts SR, George

TJ, Yothers G, Harkin A, Labianca R, Taieb J, Schmoll HJ, Twelves C, Wolmark N, Saltz LB, Souglakos I, Goldberg RM, Kerr R, Lonardi S, **Yoshino T**, Puccini A, André T, Shi Q, Sobrero A; ACCENT/IDEA Group. The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials. ***JAMA Oncol.*** 2025 Oct 2. doi: 10.1001/jamaoncol.2025.3760. Epub ahead of print. PMID: 41037274.

31. Yamamoto K, Owaki Y, Nakayama I, Sakamoto N, Ishizaka M, Kadota T, Okemoto D, Matsubara Y, Miyashita Y, Kobayashi A, Okazaki U, Seguchi K, Hosokai T, Ogura T, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Kuwata T, Ishii G, Yano T, Shitara K. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ***ESMO Open.*** 2025 Sep 30;10(10):105805. doi: 10.1016/j.esmoop.2025.105805. Epub ahead of print. PMID: 41033281.
32. Suzuki K, Miyake H, Inaki A, Takano S, Kuboki Y, Mizowaki T, Nakamura K, Ueno M, Matsumoto S, Obinata D, Nakagawa T, Murakami M, Majima Y, Yokono M, Namba M, **Yoshino T**. Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology. ***Int J Clin Oncol.*** 2025 Sep 30. doi: 10.1007/s10147-025-02858-3. Epub ahead of print. PMID: 41026359. (***Senior author***)
33. Ando K, Hamabe A, Nakamura Y, Watanabe J, Hirata K, Kataoka K, Miyo M, Kato K, Akazawa N, Kagawa Y, Yokota M, Yamazaki K, Mishima S, Yukami H, Kotani D, Bando H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Taniguchi H, Takemasa I, Kato T, **Yoshino T**, Oki E. Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study. ***Ann Surg.*** 2025 Sep 26. doi: 10.1097/SLA.0000000000006948. Epub ahead of print. PMID: 41002143.
34. Zhang F, Nakayama I, Sakamoto N, Okemoto D, Jubashi A, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Kuwata T, Shitara K. Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS $\geqslant$1 metastatic gastric/gastroesophageal junction cancer. ***Ther Adv Med Oncol.*** 2025 Sep 20;17:17588359251369042. doi: 10.1177/17588359251369042. PMID: 40985041; PMCID: PMC12450271.
35. Mori T, Kobayashi S, Tsukada Y, Kojima M, Kitaguchi D, Hasegawa H, Ikeda K, Nishizawa Y, Gotohda N, Bando H, Tsuboi M, Ito M, **Yoshino T**. Survival Outcomes of Patients with BRAF V600E-Mutant Resectable Extrahepatic Colorectal

Oligometastases After Upfront Metastasectomy. ***J Gastrointest Cancer.*** 2025 Sep 22;56(1):192. doi: 10.1007/s12029-025-01315-8. PMID: 40982073. **(*Senior author)***

36. Satake H, Bando H, Kobayashi S, **Yoshino T**. From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer. ***Med.*** 2025 Sep 12;6(9):100811. doi: 10.1016/j.medj.2025.100811. PMID: 40945506. **(*Senior & Corresponding author)***
37. Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, **Yoshino T**, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. ***J Clin Oncol.*** 2025 Sep 4:JCO2501003. doi: 10.1200/JCO-25-01003. Epub ahead of print. PMID: 40906970.
38. Kotani D, **Yoshino T**, Masuishi T, Sunakawa Y, Takashima A, Yamazaki K, Kawakami H, Nishina T, Komatsu Y, Esaki T, Eng C, Ukrainskyj S, Pallai R, Nanda S, Yang Z, Schelman W, Kania M, Satoh T. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. ***Int J Clin Oncol.*** 2025 Sep 1. doi: 10.1007/s10147-025-02852-9. Epub ahead of print. PMID: 40888992.
39. Aoki Y, Hashimoto T, Takahashi N, Okunaka M, Mishima S, Kotani D, Kawazoe A, Nakamura Y, Nakayama I, Kuboki Y, Bando H, Kojima T, Nakamura N, Sakamoto N, Ishii G, Fujisawa T, **Yoshino T**, Arai Y, Shibata T, Shitara K. Clinical Significance of Extrachromosomal DNA in FGFR2-Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience. ***JCO Precis Oncol.*** 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18. PMID: 40825170.
40. Loeffler CML, Bando H, Sainath S, Muti HS, Jiang X, van Treeck M, Reitsam NG, Carrero ZI, Meneghetti AR, Nishikawa T, Misumi T, Mishima S, Kotani D, Taniguchi H, Takemasa I, Kato T, Oki E, Tanwei Y, Durgesh W, Foersch S, Brenner H, Hoffmeister M, Nakamura Y, **Yoshino T**, Kather JN. HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer. ***Nat Commun.*** 2025 Aug 14;16(1):7561. doi: 10.1038/s41467-025-62910-8. PMID: 40813777. **(*Corresponding author)***
41. Jubashi A, Nakayama I, Sakamoto N, Takei S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Kuwata T, Sato K, Fujita T, Yoshida M, Yura M, Kinoshita T, Shitara K. Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy

in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors. ***JCO Precis Oncol.*** 2025 Aug;9:e2400925. doi: 10.1200/PO-24-00925. Epub 2025 Aug 1. PMID: 40749150; PMCID: PMC12316131.

42. Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, **Yoshino T**, Heath EI, Lou E, Liu SV, Marshall JL, El-Deiry WS, Shields AF, Dietrich MF, Nakamura Y, Fujisawa T, Demetri GD, Barker A, Xiu J, Sacchetti DA, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert DD, Oberley M, Radovich M, Sledge GW, Spetzler DB. Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. ***Sci Rep.*** 2025 Jul 1;15(1):21173. doi: 10.1038/s41598-025-08986-0. PMID: 40596693
43. Tsukada Y, Saito N, Nishizawa Y, Ohno R, Fujita F, Koda K, Ohue M, Shinto E, Murata A, Koide Y, Ikeda K, Bando H, Suzuki M, Misumi T, **Yoshino T**, Ito M. Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy for Very Low-Lying Clinical T3 Rectal Cancer: The NAIR Phase 2/3 Randomized Clinical Trial. ***Ann Surg Open.*** 2025 May 16;6(2):e579. doi: 10.1097/AS9.0000000000000579. PMID: 40557347; PMCID: PMC12185085.
44. Sato S, Rhodes SL, Aoki Y, Nakayama I, Hashimoto T, Hawkins J, Yanes RE, Chang CH, Nakamura Y, Kawazoe A, Mishima S, Kotani D, Kuboki Y, Bando H, Kojima T, Yoshino S, Reading S, Honeycutt H, Finger E, Endo I, Sakamoto N, Kuwata T, **Yoshino T**, Shitara K. Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma. ***ESMO Open.*** 2025 Jun 12;10(7):105322. doi: 10.1016/j.esmoop.2025.105322. Epub ahead of print. PMID: 40513139.
45. Yajima S, Kobayashi S, Hashimoto T, Nakamura Y, Yamashita R, Misumi T, Sakamoto Y, Horasawa S, Fujisawa T, Imai M, Shibuki T, Tsukada Y, Bando H, Masuda H, **Yoshino T.** Physical activity and cancer biology: a narrative review of molecular mechanisms and introduction of the SCRUM-MONSTAR LIFELOG study. ***Int J Clin Oncol.*** 2025 Jun 10. doi: 10.1007/s10147-025-02798-y. Epub ahead of print. PMID: 40494940. (***Senior Author)***
46. Nag S, Ray Coquard I, Gupta S, Pathak A, Li N, Mulya Sari R, Harano K, Kim GM, Ang SF, Que FV, Chay WY, Lai HC, Ativitavas T, Tangjitgamol S, Lai CH, Heong VYM, Contreras Tolentino J, Ngu MR, Yun J, Yunokawa M, Hanafi WLH, Li J, Smyth E, **Yoshino T**, Mehta J, Pentheroudakis G, Maheshwari A, Cervantes A, Basade M, Oaknin A. Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. ***ESMO Open.***

2025 Jun 9;10(6):105125. doi: 10.1016/j.esmoop.2025.105125. Epub ahead of print. PMID: 40494042.

47. Hashimoto T, Iida N, Nakamura Y, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Ogata T, Takahashi N, Okano N, Nishina T, Sakamoto N, Kuwata T, Yamashita R, Shibuki T, Imai M, Fujisawa T, Bando H, Shitara K, **Yoshino T**. Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study. ***Cancer Sci.*** 2025 Jun 2. doi: 10.1111/cas.70100. Epub ahead of print. PMID: 40455642. ***(Senior author)***
48. Elez E, **Yoshino T**, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. Encorafenib, Cetuximab, and mFOLFOX6 in *BRAF*-Mutated Colorectal Cancer. ***N Engl J Med.*** 2025 May 30. doi: 10.1056/NEJMoa2501912. Epub ahead of print. PMID: 40444708.
49. Muro K, Yamazaki K, Kadowaki S, Mishima S, Kawakami T, Tanaka T, Tada K, Fagniez N, Ohshima S, **Yoshino T**. Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors. ***Int J Clin Oncol.*** 2025 May 25. doi: 10.1007/s10147-025-02784-4. Epub ahead of print. PMID: 40413667. **(*Senior & Corresponding author)***
50. Kopetz S, **Yoshino T**, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J. The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary. ***Future Oncol.*** 2025 May 20:1-12. doi: 10.1080/14796694.2025.2491290. Epub ahead of print. PMID: 40391894.
51. Sawada K, Yamashita R, Sakai SA, Horasawa S, Yoshikawa A, Fujisawa T, Kadowaki S, Kato K, Ueno M, Oki E, Komatsu Y, Chiyoda T, Horita Y, Yasui H, Denda T, Satake H, Esaki T, Satoh T, Takahashi N, Yamazaki K, Matsuhashi N, Nishina T, Takeda H, Ohtsubo K, Ohta T, Tsuji A, Goto M, Kato T, Bando H, Tsuchihara K, Nakamura Y, **Yoshino T**. Microbiome landscape and association with response to immune checkpoint inhibitors in advanced solid tumors: a SCRUM-Japan MONSTAR-SCREEN study. ***Cancer Res Commun.*** 2025 May 9. doi: 10.1158/2767-9764.CRC-24-0543. Epub ahead of print. PMID: 40341952. **(*Senior & Corresponding author)***
52. Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, **Yoshino T**, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J. A plain language

summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study. ***Future Oncol.*** 2025 May 9:1-11. doi: 10.1080/14796694.2025.2498880. Epub ahead of print. PMID: 40340632.

53. Kato T, Shiota M, Nishimoto K, Matsubara N, Osawa T, Abe T, Yasumizu Y, Tanaka N, Yamamoto Y, Ishizuya Y, Abutani H, Bando H, Fujisawa T, Nakamura Y, Oya M, Shinohara N, Eto M, **Yoshino T**, Nonomura N. Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project. ***Br J Cancer.*** 2025 May 5. doi: 10.1038/s41416-025-02985-8. Epub ahead of print. PMID: 40325148.
54. Bachet JB, de Gramont A, Raeisi M, Rakez M, Goldberg RM, Tebbutt NC, Van Cutsem E, Haller DG, Hecht JR, Mayer RJ, Lichtman SM, Benson AB, Sobrero AF, Tabernero J, Adams R, Zalcberg JR, Grothey A, **Yoshino T**, André T, Shi Q, Chibaudel B. Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. ***J Clin Oncol.*** 2025 May 5:JCO2401968. doi: 10.1200/JCO-24-01968. Epub ahead of print. PMID: 40324123.
55. Bando H, Takeda Y, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Oki E, Douillard JY, Punt CJA, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Lenz HJ, Maehara Y, Andre T, Shi Q, de Gramont A, **Yoshino T**. Associations between early tumor shrinkage/depth of response and survivals from the ARCAD database. ***JNCI Cancer Spectr.*** 2025 Apr 25:pkaf042. doi: 10.1093/jncics/pkaf042. Epub ahead of print. PMID: 40280867. (***Senior & Corresponding author***)
56. Ohtsubo K, Sato S, Sakaguchi H, Kotani H, Nishiyama A, Yamashita K, Yano S, Toshima F, Inoue D, Gabata T, Ikeda H, Watanabe A, Notohara K, Fujisawa T, Nakamura Y, **Yoshino T**, Miyake K, Miwa K, Takeuchi S. Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor. ***Front Oncol.*** 2025 Mar 27;15:1551038. doi: 10.3389/fonc.2025.1551038. PMID: 40236650; PMCID: PMC11997870.
57. Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y, Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, **Yoshino T**. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA

Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. ***JCO Precis Oncol.*** 2025 Apr;9:e2400283. doi: 10.1200/PO.24.00283. Epub 2025 Apr 10. PMID: 40209142. ***(Senior & Corresponding author)***

58. Inoue K, Nakamura Y, Caughey B, Zheng-Lin B, Ueno M, Furukawa M, Kawamoto Y, Itoh S, Umemoto K, Sudo K, Satoh T, Mizuno N, Kajiwara T, Fujisawa T, Bando H, **Yoshino T**, Strickler JH, Morizane C, Bekaii-Saab T, Ikeda M. Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2-Amplified Advanced Biliary Tract Cancer. ***JCO Precis Oncol.*** 2025 Apr;9:e2400718. doi: 10.1200/PO-24-00718. Epub 2025 Apr 10. PMID: 40209139.
59. Matsukawa M, Tomozawa C, Nakamura Y, Fujisawa T, Kimura K, Hiraoka Y, Yamashita R, Kosugi S, Sakurai A, Imoto I, Nishigaki M, Hirata M, Kuwata T, **Yoshino T**. Establishment of a comprehensive set of fact sheets for cancer predisposition genes for medical oncologists practicing cancer genome profiling. ***Int J Clin Oncol.*** 2025 Apr 4. doi: 10.1007/s10147-025-02746-w. Epub ahead of print. PMID: 40183848. ***(Senior & Corresponding author)***
60. Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, **Yoshino T**, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Yang Z, Guevara F, Schelman W, Pallai R, Tabernero J. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. ***Oncologist.*** 2025 Mar 10;30(3):oyae360. doi: 10.1093/oncolo/oyae360. PMID: 40163688.
61. Sasaki A, Chihara S, Okamoto R, **Yoshino T**, Nakamura Y. Exceptional response to brigatinib following alectinib failure in a patient with ALK fusion-positive duodenal carcinoma. ***Int Cancer Conf J.*** 2025 Feb 10;14(2):131-135. doi: 10.1007/s13691-025-00745-2. PMID: 40160872; PMCID: PMC11950605.
62. Hoyek C, Pirozzi A, Zheng B, Lida N, Ramaker R, Abidoye S, Eslinger C, Shibuki T, Wu CSY, Sonbol MB, Ahn DH, Borad M, Ikeda M, Nakamura Y, Rimassa L, **Yoshino T**, Strickler J, Bekaii-Saab T. CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC). ***J Natl Compr Canc Netw.*** 2025 Mar 28;23(3.5):CLO25-095. doi: 10.6004/jnccn.2024.7161. PMID: 40154374.
63. Takei S, Kotani D, Laliotis G, Sato K, Fujiwara N, Kawazoe A, Hashimoto T, Mishima S, Nakayama I, Nakamura Y, Bando H, Kuboki Y, Sakashita S, Spickard E, George GV, Dutta P, Sharma S, Malhotra M, Sethi H, Jurdi A, Liu MC, **Yoshino T**, Shitara K, Kojima T, Fujita T. Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A

Prospective Observational Study. ***Ann Surg.*** 2025 Mar 21. doi: 10.1097/SLA.0000000000006699. Epub ahead of print. PMID: 40115982.

64. Sledge GW Jr, **Yoshino T**, Xiu J, Helmstetter A, Ribeiro JR, Klimov S, Gilg B, Gao JJ, Elton J, Oberley MJ, Radovich M, Abraham J, Spetzler D. Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. ***Nat Commun.*** 2025 Mar 18;16(1):2646. doi: 10.1038/s41467-025-57941-0. PMID: 40102447.
65. Cohen R, Raeisi M, Chibaudel B, Yothers G, Goldberg RM, Bachet JB, Wolmark N, **Yoshino T**, Schmoll HJ, Haller DG, Kerr R, Lonardi S, George TJ, Shacham-Shmueli E, Shi Q, André T, de Gramont A. Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis. ***ESMO Open.*** 2025 Mar 4;10(3):104481. doi: 10.1016/j.esmoop.2025.104481. Epub ahead of print. PMID: 40043353.
66. Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K, Oki E, Satoh T, Aoki D, Yamazaki K, Esaki T, Ueno M, Nishina T, Sunakawa Y, Denda T, Bando H, Kuramoto N, Horasawa S, Abutani H, Lee JK, Madison RW, Oxnard GR, **Yoshino T**. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. ***J Liq Biopsy.*** 2023 Aug 10;1:100003. doi: 10.1016/j.jlb.2023.100003. PMID: 40027285; PMCID: PMC11863975. ***(Senior & Corresponding Author)***
67. Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, **Yoshino T**, Nonomura N. Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project. ***J Liq Biopsy.*** 2024 Dec 20;7:100282. doi: 10.1016/j.jlb.2024.100282. PMID: 40027233; PMCID: PMC11863810.
68. Stintzing S, Tabernero J, Satoh T, Dasari A, Lonardi S, Eng C, Garcia-Carbonero R, Elez E, **Yoshino T**, Sobrero AF, Yao JC, Kasper S, Arnold D, Basic E, Granold M, Petschulies M, Wu L, Chung YC, Chen L, Yang Z, Van Cutsem E. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2. ***ESMO Open.*** 2025 Feb 21;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub ahead of print. PMID: 39985889.
69. Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, Tanaka Y, Habu T, Fukaya S, Kondo M, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukui M, Fuse N, Koyama S, Mano H, Nishikawa H, Shitara K, **Yoshino T**, Kojima T. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced

esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). ***Nat Cancer.*** 2025 Feb 19. doi: 10.1038/s43018-025-00918-1. Epub ahead of print. PMID: 39972105.

70. Sakai SA, Nomura R, Nagasawa S, Chi S, Suzuki A, Suzuki Y, Imai M, Nakamura Y, **Yoshino T**, Ishikawa S, Tsuchihara K, Kageyama SI, Yamashita R. SpatialKNifeY (SKNY): Extending from spatial domain to surrounding area to identify microenvironment features with single-cell spatial omics data. ***PLoS Comput Biol.*** 2025 Feb 18;21(2):e1012854. doi: 10.1371/journal.pcbi.1012854. Epub ahead of print. PMID: 39965034.
71. Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, **Yoshino T**, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Price T, Yu Z, Geiger A, Chen L, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. ***Eur J Cancer.*** 2025 Jan 29;218:115268. doi: 10.1016/j.ejca.2025.115268. Epub ahead of print. PMID: 39952149.
72. Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, Horinouchi H, Ozaki Y, Iwata H, Kato T, Miyake H, Ohba A, Ikeda M, Chiyoda T, Hasegawa K, Fujisawa T, Matsuura K, Namikawa K, Yajima S, **Yoshino T**, Hasegawa K. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. ***Int J Clin Oncol.*** 2025 Feb 7. doi: 10.1007/s10147-024-02683-0. Epub ahead of print. PMID: 39920551.
73. André T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, Garcia-Carbonero R, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, **Yoshino T**, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. ***Lancet.*** 2025 Jan 23:S0140-6736(24)02848-4. doi: 10.1016/S0140-6736(24)02848-4. Epub ahead of print. PMID: 39874977.
74. Chen LT, Vogel A, Hsu C, Chen MH, Fang W, Pangarsa EA, Sharma A, Ikeda M, Park JO, Tan CK, Regala E, Tai D, Tanasanvimon S, Charoentum C, Chee CE, Lui A, Sow J, Oh DY, Ueno M, Ramaswamy A, Jeo WS, Zhou J, Curigliano G, **Yoshino T,** Bai LY, Pentheroudakis G, Chiang NJ, Cervantes A, Chen JS, Ducreux M. Corrigendum to "Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer": [ESMO Open 9 (2024) 103647].

ESMO Open. 2025 Jan;10(1):104074. doi: 10.1016/j.esmoop.2024.104074. Epub 2024 Dec 19. Erratum for: ESMO Open. 2024 Aug;9(8):103647. doi: 10.1016/j.esmoop.2024.103647. PMID: 39864890.

75. Kopetz S, **Yoshino T**, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Beyzarov E, Zhang X, Ferrier G, Zhang X, Tabernero J. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. ***Nat Med.*** 2025 Jan 25. doi: 10.1038/s41591-024-03443-3. Epub ahead of print. PMID: 39863775.
76. Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Sawada K, Sato A, Kuwata T, Yamashita R, Fujisawa T, Bando H, Ock CY, Fujii S, **Yoshino T.** Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. ***JCO Precis Oncol.*** 2025 Jan;9:e2400385. doi: 10.1200/PO-24-00385. Epub 2025 Jan 17. PMID: 39823559. ***(Senior Author)***
77. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, **Yoshino T**. Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. ***Nat Commun.*** 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9. Erratum for: Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. PMID: 39814812. ***(Senior author)***
78. Imai M, Nakamura Y, **Yoshino T**. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies. ***Int J Clin Oncol.*** 2025 Jan 12. doi: 10.1007/s10147-025-02694-5. Epub ahead of print. PMID: 39799530. ***(Senior & Corresponding author)***

79. Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, **Yoshino T**, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. ***Future Oncol.*** 2024 Dec 26:1-9. doi: 10.1080/14796694.2024.2441101. Epub ahead of print. PMID: 39723627.
80. Bando H, Naito Y, Yamada T, Fujisawa T, Imai M, Sakamoto Y, Saigusa Y, Yamamoto K, Tomioka Y, Takeshita N, Sunami K, Futamura M, Notake C, Aoki S, Okano K, **Yoshino T**. A prospective study comparing highly qualified Molecular Tumor Boards with

AI-powered software as a medical device. ***Int J Clin Oncol.*** 2024 Dec 23. doi: 10.1007/s10147-024-02684-z. Epub ahead of print. PMID: 39714567. *(Senior & Corresponding Author)*

81. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere C, Rivera F, Elez E, Le DT, **Yoshino T**, Zuo Y, Fogelman D, Adelberg D, Diaz LA Jr. Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study. ***Ann Oncol.*** 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.11.012. Epub ahead of print. PMID: 39631622.
82. Lee SH, Menis J, Kim TM, Kim HR, Zhou C, Kurniawati SA, Prabhash K, Hayashi H, Lee DD, Imasa MS, Teh YL, Yang JC, Reungwetwattana T, Sriuranpong V, Wu CE, Ang Y, Sabando M, Thiagarajan M, Mizugaki H, Noronha V, Yulianti M, Zhang L, Smyth E, **Yoshino T**, Park JO, Pentheroudakis G, Park S, Peters S, Ahn JB, Popat S. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer. ***ESMO Open.*** 2024 Nov 29;9(12):103996. doi: 10.1016/j.esmoop.2024.103996. Epub ahead of print. PMID: 39615406.
83. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, **Yoshino T**, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. ***N Engl J Med.*** 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. PMID: 39602630.
84. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, **Yoshino T**. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. ***Nat Commun.*** 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. PMID: 39587050. (***Senior author***)
85. Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, **Yoshino T**. Different efficacy of tyrosine kinase

inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors. ***BJC Rep.*** 2024 Jul 25;2(1):54. doi: 10.1038/s44276-024-00073-7. PMID: 39516322. (***Senior author***)

86. Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, **Yoshino T**, Nonomura N. Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project. ***BJC Rep.*** 2024 Apr 3;2(1):28. doi: 10.1038/s44276-024-00049-7. PMID: 39516321.
87. Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, **Yoshino T**, Sasser K, Oki E, Nimeiri H. A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan. ***Clin Cancer Res.*** 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396. Epub ahead of print. PMID: 39513962.
88. Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Miyaaki H, Nakao K, Shitara K. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. ***Gastric Cancer.*** 2024 Nov 2. doi: 10.1007/s10120-024-01560-z. Epub ahead of print. PMID: 39487862.
89. Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, **Yoshino T**, Aoki D. Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer. ***J Gynecol Oncol.*** 2024 Oct 21. doi: 10.3802/jgo.2025.36.e38. Epub ahead of print. PMID: 39453391.
90. von der Heyde S, Raman N, Gabelia N, Matias-Guiu X, **Yoshino T**, Tsukada Y, Melino G, Marshall JL, Wellstein A, Juhl H, Landgrebe J. Tumor specimen cold ischemia time impacts molecular cancer drug target discovery. ***Cell Death Dis.*** 2024 Sep 26;15(9):691. doi: 10.1038/s41419-024-07090-x. PMID: 39327466; PMCID: PMC11427669.
91. Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, **Yoshino T**, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J. Molecular profiling of

BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. ***Nat Med.*** 2024 Sep 23. doi: 10.1038/s41591-024-03235-9. Epub ahead of print. PMID: 39313594.

92. Stintzing S, **Yoshino T**. Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. ***Eur J Cancer.*** 2024 Oct;210:114298. doi: 10.1016/j.ejca.2024.114298. Epub 2024 Aug 22. PMID: 39304280. ***(Senior Author)***
93. Kataoka K, Mori K, Nakamura Y, Watanabe J, Akazawa N, Hirata K, Yokota M, Kato K, Kotaka M, Yamazaki K, Kagawa Y, Mishima S, Ando K, Miyo M, Yukami H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kotani D, Bando H, Taniguchi H, Takemasa I, Kato T, **Yoshino T**, Oki E. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY. ***Ann Oncol.*** 2024 Aug 21:S0923-7534(24)03763-3. doi: 10.1016/j.annonc.2024.08.2240. Epub ahead of print. PMID: 39293512.
94. Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, **Yoshino T**, Nonomura N. Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project. ***World J Urol.*** 2024 Sep 18;42(1):526. doi: 10.1007/s00345-024-05240-6. PMID: 39292288.
95. Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, **Yoshino T**, Oki E. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. ***Nat Med.*** 2024 Sep 16. doi: 10.1038/s41591-024-03254-6. Epub ahead of print. PMID: 39284954. ***(Corresponding Author)***
96. Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, **Yoshino T**. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. ***Nat Med.*** 2024 Sep 16. doi: 10.1038/s41591-024-03244-8. Epub ahead of print. PMID: 39284955.

(Senior & Corresponding Author)

97. Chen LT, Vogel A, Hsu C, Chen MH, Fang W, Pangarsa EA, Sharma A, Ikeda M, Park JO, Tan CK, Regala E, Tai D, Tanasanvimon S, Charoentum C, Chee CE, Lui A, Sow J, Oh DY, Ueno M, Ramaswamy A, Jeo WS, Zhou J, Curigliano G, **Yoshino T**, Bai LY, Pentheroudakis G, Chiang NJ, Cervantes A, Chen JS, Ducreux M. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. ***ESMO Open.*** 2024 Aug;9(8):103647. doi: 10.1016/j.esmoop.2024.103647. Epub 2024 Aug 6. PMID: 39232586.
98. Chibaudel B, Raeisi M, Cohen R, Yothers G, Goldberg RM, Bachet JB, Wolmark N, **Yoshino T**, Schmoll HJ, Kerr R, Lonardi S, George TJ, Shacham-Shmueli E, Shi Q, André T, de Gramont A. Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis. ***J Clin Oncol.*** 2024 Sep 4:JCO2400394. doi: 10.1200/JCO.24.00394. Epub ahead of print. PMID: 39231393.
99. Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, **Yoshino T**, Ikeda M, Morizane C. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. ***Br J Cancer.*** 2024 Aug 28. doi: 10.1038/s41416-024-02834-0. Epub ahead of print. PMID: 39198618.
100. Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, **Yoshino T**, Nakamura Y. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. ***Clin Cancer Res.*** 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023. Epub ahead of print. PMID: 39163021.
101. Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, **Yoshino T**. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. ***Lancet Oncol.*** 2024

Aug 5:S1470-2045(24)00380-2. doi: 10.1016/S1470-2045(24)00380-2. Epub ahead of print. PMID: 39116902. *(Senior author)*

102. Nakamura Y, Tsukada Y, Matsuhashi N, Murano T, Shiozawa M, Takahashi Y, Oki E, Goto M, Kagawa Y, Kanazawa A, Ohta T, Ouchi A, Bando H, Uchigata H, Notake C, Ikematsu H, **Yoshino T**. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. *Clin Cancer Res.* 2024 Aug 7. doi: 10.1158/1078-0432.CCR-24-1651. Epub ahead of print. PMID: 39110016. *(Senior author)*

103. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, **Yoshino T**, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. *J Clin Oncol.* 2024 Aug 5:JCO2302010. doi: 10.1200/JCO.23.02010. Epub ahead of print. PMID: 39102634.

104. Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, Komatsu Y, Esaki T, Sakai D, Doi A, Kajiwara T, Ono H, Asano M, Hirano N, Odegaard J, Fujii S, Nomura S, Bando H, Sato A, **Yoshino T**, Nakamura Y. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. *J Clin Oncol.* 2024 Aug 1:JCO2302626. doi: 10.1200/JCO.23.02626. Epub ahead of print. PMID: 39088783.

105. Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, **Yoshino T**. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. *Cancer Discov.* 2024 Jul 18. doi: 10.1158/2159-8290.CD-24-0206. Epub ahead of print. PMID: 39023403. *(Senior & Corresponding Author)*

106. Osumi H, Shinozaki E, Nakamura Y, Esaki T, Yasui H, Taniguchi H, Satake H, Sunakawa Y, Komatsu Y, Kagawa Y, Denda T, Shiozawa M, Satoh T, Nishina T, Goto M, Takahashi N, Kato T, Bando H, Yamaguchi K, **Yoshino T**. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. *Nat Commun.* 2024 Jul 13;15(1):5885. doi:

10.1038/s41467-024-50026-4. PMID: 39003289; PMCID: PMC11246505. ***(Senior & Corresponding Author)***

107. Eng C, **Yoshino T**, Ruíz-García E, Mostafa N, Cann CG, O'Brian B, Benny A, Perez RO, Cremolini C. Colorectal cancer. ***Lancet.*** 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360-X. Epub ahead of print. PMID: 38909621.
108. Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, **Yoshino T**, Kato T, Tsuji A. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. ***Med.*** 2024 Jun 14:S2666-6340(24)00216-2. doi: 10.1016/j.medj.2024.05.012. Epub ahead of print. PMID: 38901425.
109. Cohen R, Raeisi M, Chibaudel B, Shi Q, **Yoshino T**, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA, Arnold D, Hurwitz HI, Douillard JY, Venook AP, Saltz LB, Maughan TS, Kabbinavar F, Bokemeyer C, Grothey A, Mayer RJ, Kaplan R, Tebbutt NC, Randolph Hecht J, Giantonio BJ, Díaz-Rubio E, Sobrero AF, Peeters M, Koopman M, Goldberg RM, Andre T, de Gramont A. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. ***Eur J Cancer.*** 2024 Jun 10;207:114160. doi: 10.1016/j.ejca.2024.114160. Epub ahead of print. PMID: 38896997.
110. Taieb J, Basile D, Seligmann J, Argiles G, André T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt JA, Souglakos J, Labianca R, Iveson T, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, **Yoshino T**, Lonardi S, Shi Q. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. ***Eur J Cancer.*** 2024 May 15;206:114118. doi: 10.1016/j.ejca.2024.114118. Epub ahead of print. PMID: 38810317.
111. Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, Kotani D, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Sato A, Nishikawa H, Ito M, **Yoshino T**. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer. ***Br J Cancer.*** 2024 Jun 4. doi: 10.1038/s41416-024-02730-7. Epub ahead of print. PMID: 38834744.
112. Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M,

Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, **Yoshino T**, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. ***J Clin Oncol.*** 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736. Epub ahead of print. PMID: 38833658.

113. Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, **Yoshino T**, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer. ***ESMO Open.*** 2024 May;9(5):102974. doi: 10.1016/j.esmoop.2024.102974. Epub 2024 Apr 12. PMID: 38796284.

114. Takashima A, García-Alfonso P, Manneh R, Beşen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, **Yoshino T**, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. ***Eur J Cancer.*** 2024 Jul;205:114036. doi: 10.1016/j.ejca.2024.114036. Epub 2024 Mar 21. PMID: 38749110.

115. Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, **Yoshino T**, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. ***Ann Surg Oncol.*** 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2. Epub 2024 Feb 14. PMID: 38353798.

116. Bando H, Misumi T, Sakamoto Y, Takeda Y, Nakamura Y, Mizuguchi K, Aoyagi Y, Miki I, Kuroda T, Kasai R, Suzuki T, **Yoshino T**, Ohtsu A. Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission. ***Clin Colorectal Cancer.*** 2024 Apr 6:S1533-0028(24)00025-2. doi: 10.1016/j.clcc.2024.04.001. Epub ahead of print. PMID: 38679555.

117. Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, Fujisawa T, Imai M, Nakamura Y, Bando H, Kawaguchi T, **Yoshino T**, Iwata H. Genomic

Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project. ***JCO Precis Oncol.*** 2024 Apr;8:e2300647. doi: 10.1200/PO.23.00647. PMID: 38635933.

118. Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, Kobayashi S, Furukawa M, Lee L, Satoh T, Sakai D, Ikeda M, Imaoka H, Miura A, Hatanaka Y, Yokota I, Nakamura Y, **Yoshino T**. Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. ***Future Oncol.*** 2024 Apr 17. doi: 10.2217/fon-2023-0348. Epub ahead of print. PMID: 38629456. ***(Senior Author)***

119. Karapetis CS, Liu H, Sorich MJ, Pederson LD, Van Cutsem E, Maughan T, Douillard JY, O'Callaghan CJ, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, **Yoshino T**, de Gramont A, Shi Q. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. ***Br J Cancer.*** 2024 May;130(8):1269-1278. doi: 10.1038/s41416-024-02604-y. Epub 2024 Feb 24. PMID: 38402342.

120. Augustyniak M, Lou E, Jacobs G, Fleming M, Marshall J, Coutinho A, **Yoshino T**. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers. ***J Cancer Educ.*** 2024 Apr;39(2):118-125. doi: 10.1007/s13187-023-02384-8. Epub 2023 Dec 23. PMID: 38135836; PMCID: PMC10995009. ***(Senior Author)***

121. Hashimoto T, Nakamura Y, Oki E, Kobayashi S, Yuda J, Shibuki T, Bando H, **Yoshino T**. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. ***Int J Clin Oncol.*** 2024 Mar 29. doi: 10.1007/s10147-024-02493-4. Epub ahead of print. PMID: 38551727. ***(Senior & Corresponding Author)***

122. Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, **Yoshino T**, Goldberg RM, Taieb J, Papamichael D. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. ***J Clin Oncol.*** 2024 Mar

28:JCO2301326. doi: 10.1200/JCO.23.01326. Epub ahead of print. PMID: 38547438.

123. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, **Yoshino T**, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. ***Future Oncol.*** 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249. Epub 2023 Oct 10. PMID: 37815847.

124. Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, **Yoshino T**. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. ***Nat Rev Gastroenterol Hepatol.*** 2024 Mar 14. doi: 10.1038/s41575-024-00900-9. Epub ahead of print. PMID: 38485756. ***(Senior & Corresponding Author)***

125. Lenz HJ, Parikh A, Spigel DR, Cohn AL, **Yoshino T**, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. ***J Immunother Cancer.*** 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409. PMID: 38485190.

126. Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, Shiozawa M, Esaki T, Izawa N, Takeuchi S, Bando H, Iwasa S, Hasegawa H, Yamaguchi T, Taniguchi H, Ushida Y, Oizaki T, Inoue C, **Yoshino T**. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for $BRAF^{V600E}$-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program. ***Clin Colorectal Cancer.*** 2024 Mar 9:S1533-0028(24)00022-7. doi: 10.1016/j.clcc.2024.02.002. Epub ahead of print. PMID: 38553360. ***(Senior & Corresponding Author)***

127. Miyashita Y, Kawazoe A, **Yoshino T**. [Chemotherapy for Unresectable Advanced, Metastatic or Recurrent Colorectal Cancer]. ***Gan To Kagaku Ryoho.*** 2024 Mar;51(3):245-249. Japanese. PMID: 38494801.

128. Tabernero J, Taieb J, Fakih M, Prager GW, Van Cutsem E, Ciardiello F, Mayer RJ, Amellal N, Skanji D, Calleja E, **Yoshino T**. Impact of $KRAS^{G12}$ mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ***ESMO Open.*** 2024 Mar 11;9(3):102945. doi: 10.1016/j.esmoop.2024.102945. Epub ahead of print. PMID: 38471240. ***(Senior Author)***

129. Shitara K, Fleitas T, Kawakami H, Curigliano G, Narita Y, Wang F, Wardhani SO, Basade M, Rha SY, Wan Zamaniah WI, Sacdalan DL, Ng M, Yeh KH, Sunpaweravong P, Sirachainan E, Chen MH, Yong WP, Peneyra JL, Ibtisam MN, Lee KW, Krishna V, Pribadi RR, Li J, Lui A, **Yoshino T**, Baba E, Nakayama I, Pentheroudakis G, Shoji H, Cervantes A, Ishioka C, Smyth E. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ***ESMO Open.*** 2024 Feb;9(2):102226. doi: 10.1016/j.esmoop.2023.102226. Epub 2024 Feb 3. PMID: 38458658.

130. **Yoshino T**, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, O'neil BH, Herrero FR, Peeters M, Soeda J, Suh M, Reichert H, Mezzi K, Fryzek J, Chia V, Rehn M, Stintzing S. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. ***Eur J Cancer.*** 2024 Mar 1;202:113975. doi: 10.1016/j.ejca.2024.113975. Epub ahead of print. PMID: 38442645.

131. Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, Kuboki Y, Bando H, Kojima T, Iida N, Shibuki T, Imai M, Fujisawa T, Nagamine M, Sakamoto N, Kuwata T, **Yoshino T**, Shitara K. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. ***Cancer Sci.*** 2024 Mar 1. doi: 10.1111/cas.16109. Epub ahead of print. PMID: 38429886.

132. Okunaka M, Kotani D, Fujiwara H, Sato K, Fujiwara N, Mishima S, Sakashita S, **Yoshino T**, Fujita T, Kojima T. Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. ***Ther Adv Med Oncol.*** 2024 Feb 22;16:17588359241229432. doi: 10.1177/17588359241229432. PMID: 38405034; PMCID: PMC10894542.

133. Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, **Yoshino T**. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. ***Nat Med.*** 2024 Feb 12. doi: 10.1038/s41591-023-02791-w. Epub ahead of print. PMID: 38347302.

134. Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M,

Sakamoto N, Kojima M, Kuwata T, **Yoshino T**, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. ***J Immunother Cancer.*** 2024 Feb 8;12(2):e008210. doi: 10.1136/jitc-2023-008210. PMID: 38336371.

135. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, **Yoshino T**. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. ***Clin Colorectal Cancer.*** 2024 Jan 18:S1533-0028(24)00003-3. doi: 10.1016/j.clcc.2024.01.003. Epub ahead of print. PMID: 38331650.
136. Cohen R, Raeisi M, Chibaudel B, **Yoshino T**, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, André T, de Gramont A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. ***Eur J Cancer.*** 2024 Jan 15;199:113537. doi: 10.1016/j.ejca.2024.113537. Epub ahead of print. PMID: 38241818.
137. Okunaka M, Kotani D, Mishima S, Nakamura M, Kawazoe A, Bando H, **Yoshino T**, Shitara K. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. ***Integr Cancer Ther.*** 2024 Jan-Dec;23:15347354231225962. doi: 10.1177/15347354231225962. PMID: 38240253.
138. Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, **Yoshino T**, Kuwata T, Shitara K. Corrigendum to "Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer": [ESMO Open 8 (2023) 100762]. ESMO Open. 2024 Jan 8;9(1):102232. doi: 10.1016/j.esmoop.2023.102232. Epub ahead of print. Erratum for: ***ESMO Open.*** 2023 Feb;8(1):100762. PMID: 38194883.
139. Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, **Yoshino T**. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A

Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. ***Target Oncol.*** 2024 Jan 9. doi: 10.1007/s11523-023-01027-8. Epub ahead of print. PMID: 38194163. (Senior author)

140. Tabernero J, **Yoshino T**, Stintzing S, de Gramont A, Gibbs P, Jonker D, Nygren P, Papadimitriou CA, Prager GW, Tell R, Lenz HJ. A Randomized Phase III Study of Arfolitixorin Versus Leucovorin with 5-Fluorouracil, Oxaliplatin and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. ***Cancer Res Commun.*** 2023 Dec 7. doi: 10.1158/2767-9764.CRC-23-0361. Epub ahead of print. PMID: 38059497.
141. Bando H, Takeda Y, Misumi T, Suzuki M, Wakabayashi M, Ohtsu A, **Yoshino T**. [Integration Process of Clinical Trial Data in ARCAD-Asia]. ***Gan To Kagaku Ryoho.*** 2023 Oct;50(10):1021-1026. Japanese. PMID: 38035827. ***(Senior author)***
142. Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, **Yoshino T**. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. ***JAMA Oncol.*** 2023 Nov 30. doi: 10.1001/jamaoncol.2023.5120. Epub ahead of print. PMID: 38032680. ***(Corresponding author)***
143. Caughey BA, Umemoto K, Green MF, Ikeda M, Lowe ME, Ueno M, Niedzwiecki D, Taniguchi H, Walden DJ, Komatsu Y, D'Anna R, Esaki T, Denda T, Datto MB, Bando H, Bekaii-Saab T, **Yoshino T**, Strickler JH, Nakamura Y. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas. ***J Gastrointest Oncol.*** 2023 Oct 31;14(5):2083-2096. doi: 10.21037/jgo-23-114. Epub 2023 Sep 19. PMID: 37969845; PMCID: PMC10643595.
144. Kajiwara T, Nishina T, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Yamamoto Y, Yamazaki K, **Yoshino T**, Hyodo I. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). ***Cancers (Basel).*** 2023 Oct 27;15(21):5172. doi: 10.3390/cancers15215172. PMID: 37958346.

145. Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. *Future Oncol.* 2023 Oct 18. doi: 10.2217/fon-2023-0282. Epub ahead of print. PMID: 37850363.
146. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170. *Eur J Cancer. 2023* Sep 28:113339. doi: 10.1016/j.ejca.2023.113339. Epub ahead of print. Erratum for: Eur J Cancer. 2023 Jan;178:162-170. PMID: 37813779.
147. Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, Doi T, Yoshino T, Kuronita T, Elenbaas B, Wahra P, Zhang H, Crowley L, Jenkins MH, Clark A, Kojima T. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. *Sci Rep.* 2023 Sep 25;13(1):16017. doi: 10.1038/s41598-023-40612-9. PMID: 37749105.
148. Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kagawa Y, Takahashi N, Denda T, Esaki T, Kawakami H, Satake H, Takashima A, Matsuhashi N, Kato T, Asano C, Abe Y, Nomura S, Yoshino T. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. *Cancer Med.* 2023 Aug 28. doi: 10.1002/cam4.6486. Epub ahead of print. PMID: 37641470.
149. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. *Cancers (Basel).* 2023 Aug 15;15(16):4117. doi: 10.3390/cancers15164117. PMID: 37627145.
150. Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, André T, Laurent-Puig P, Shi Q. Different prognostic values of KRAS exon 2 sub-mutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage

III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials. *Ann Oncol.* 2023 Aug 22:S0923-7534(23)00804-9. doi: 10.1016/j.annonc.2023.08.006. Epub ahead of print. PMID: 37619846.

151. Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Élez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study. *Clin Cancer Res.* 2023 Aug 23:CCR-23-1379. doi: 10.1158/1078-0432.CCR-23-1379. Epub ahead of print. PMID: 37610454.
152. Kobayashi S, Bando H, Taketomi A, Takamoto T, Shinozaki E, Shiozawa M, Hara H, Yamazaki K, Komori K, Matsuhashi N, Kato T, Kagawa Y, Yokota M, Oki E, Komine K, Takahashi S, Wakabayashi M, Yoshino T. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases. *BMC Cancer.* 2023 Aug 21;23(1):779. doi: 10.1186/s12885-023-11311-5. PMID: 37605122.
153. Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. *Int J Clin Oncol.* 2023 Aug 20. doi: 10.1007/s10147-023-02397-9. Epub ahead of print. PMID: 37599324.
154. Ohtsu A, Goto K, Yoshino T. Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. *Proc Jpn Acad Ser B Phys Biol Sci.* 2023 Aug 9. doi: 10.2183/pjab.99.015. Epub ahead of print. PMID: 37558430.
155. Nocini R, Tondulli L, D'Ambrosio C, Luchini C, Biankin AV, Casolino R, Scarpa A; ICGC-ARGO; Milella M, Lawlor RT. ICGC ARGO precision medicine: genomic profiling-informed prediction of immunotherapy response in two patients with metastatic head and neck squamous cell carcinoma. *Lancet Oncol.* 2023 Aug;24(8):851-853. doi: 10.1016/S1470-2045(23)00241-3. PMID: 37541270.

ICGC-ARGO: Andrew V Biankin, Lincoln D Stein, Keunchil Park, Rita T Lawlor,

Amber L Johns, Jan O Korbel, Nik Zeps, Mark A Rubin, Marco A Marra, Olivier Elemento, Steven Gallinger, David Tuveson, Lorenz Trumper, Raphael Koch, Aldo Scarpa, Paul Brennan, Christian Pilarsky, Sergey Nikolaev, Sun-Soo Yoon, Eun Sook Lee, Tatsuhiro Shibata, Xiaojian Wu, Jianmin Wu, Qimin Zhan, Wai Poon, **Takayuki Yoshino,** Khawla S Al-Kuraya, Rosalind Eeles, Rebecca Fitzgerald, Carlos Caldas, Jean Abraham, David K Chang

156. Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, Esaki T, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, **Yoshino T**, Maehara Y, Oki E. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study). ***Br J Cancer.*** 2023 Aug 2. doi: 10.1038/s41416-023-02378-9. Epub ahead of print. PMID: 37532830.
157. **Yoshino T**, Shi Q, Misumi T, Bando H, Wakabayashi M, Raeisi M, Andre T, de Gramont A. A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative. ***Nat Med.*** 2023 Jul 28. doi: 10.1038/s41591-023-02488-0. Epub ahead of print. PMID: 37507606. ***(First & Corresponding author)***
158. Strickler JH, **Yoshino T**, Stevinson K, Eichinger CS, Giannopoulou C, Rehn M, Modest DP. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. ***Oncologist.*** 2023 Jul 11:oyad138. doi: 10.1093/oncolo/oyad138. Epub ahead of print. PMID: 37432264.
159. Aoki Y, Nakamura Y, Denda T, Ohta T, Esaki T, Shiozawa M, Yamaguchi K, Yamazaki K, Sunakawa Y, Kato T, Okano N, Taniguchi H, Sato T, Oki E, Nishina T, Komatsu Y, Matsuhashi N, Goto M, Yasui H, Ohtsubo K, Moriwaki T, Takahashi N, Horita Y, Boku S, Wakabayashi M, Ikeno T, Mitani R, Yuasa M, **Yoshino T**. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy. ***JCO Precis Oncol.*** 2023 Jun;7:e2200688. doi: 10.1200/PO.22.00688. PMID: 37343204.
160. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, **Yoshino T**, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer

(FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. ***Lancet.*** 2023 Jun 15:S0140-6736(23)00772-9. doi: 10.1016/S0140-6736(23)00772-9. Epub ahead of print. PMID: 37331369.

161. Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, **Yoshino T**, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. ***Int J Clin Oncol.*** 2023 Jun 10. doi: 10.1007/s10147-023-02360-8. Epub ahead of print. PMID: 37300720.

162. **Yoshino T**, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S; DESTINY-CRC01 investigators. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. ***Nat Commun.*** 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4. PMID: 37286557. ***(First author)***

163. **Yoshino T**, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA, Tan CK, Cornelio G, Chong DQ, Chen LT, Tanasanvimon S, Prasongsook N, Yeh KH, Chua C, Sacdalan MD, Sow Jenson WJ, Kim ST, Chacko RT, Syaiful RA, Zhang SZ, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ***ESMO Open.*** 2023 May 24;8(3):101558. doi: 10.1016/j.esmoop.2023.101558. Epub ahead of print. PMID: 37236086. ***(First & Corresponding author)***

164. Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, **Yoshino T**, Baba E. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine

kinase fusion-positive advanced solid tumors. ***Int J Clin Oncol.*** 2023 May 22. doi: 10.1007/s10147-023-02345-7. Epub ahead of print. PMID: 37212982.

165. Kitaguchi D, Tsukada Y, Ito M, Horasawa S, Bando H, **Yoshino T**, Yamada K, Ajioka Y, Sugihara K. Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma. ***Eur J Surg Oncol.*** 2023 May 4:S0748-7983(23)00488-2. doi: 10.1016/j.ejso.2023.05.004. Epub ahead of print. PMID: 37210274.
166. Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, Fadjari TH, Tamura K, Mastura MY, Abesamis-Tiambeng MLT, Lim EH, Lin CH, Sookprasert A, Parinyanitikul N, Tseng LM, Lee SC, Caguioa P, Singh M, Naito Y, Hukom RA, Smruti BK, Wang SS, Kim SB, Lee KH, Ahn HK, Peters S, Kim TW, **Yoshino T**, Pentheroudakis G, Curigliano G, Harbeck N. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ***ESMO Open.*** 2023 May 11;8(3):101541. doi: 10.1016/j.esmoop.2023.101541. Epub ahead of print. PMID: 37178669.
167. Le DT, Diaz LA Jr, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil BH, Kavan P, **Yoshino T**, Guimbaud R, Taniguchi H, Élez E, Al-Batran SE, Boland PM, Cui Y, Leconte P, Marinello P, André T. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. ***Eur J Cancer.*** 2023 Feb 24;186:185-195. doi: 10.1016/j.ejca.2023.02.016. Epub ahead of print. PMID: 37141828.
168. Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, **Yoshino T**. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. ***JAMA.*** 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. PMID: 37071094. **(Corresponding author)**
169. Aibe N, Ogino H, Wakatsuki M, Fujikawa K, Teramukai S, Fukumitsu N, Shiba S, Yamamoto N, Nomoto A, Ono T, Oguri M, Yamaguchi H, Numajiri H, Shibuya K, Okazaki S, Miyasaka Y, Okonogi N, Murata K, Tatebe H, Motegi A, Okimoto T, **Yoshino T**, Mandai M, Katoh N, Tsuji H, Sakurai H. Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray

radiotherapy. ***J Radiat Res.*** 2023 Apr 13:rrad004. doi: 10.1093/jrr/rrad004. Epub ahead of print. PMID: 37053162.

170. Nakamura Y, Yamashita R, Okamoto W, Komatsu Y, Yuki S, Ueno M, Kato K, Taniguchi H, Kagawa Y, Denda T, Hara H, Esaki T, Moriwaki T, Sunakawa Y, Oki E, Nagashima F, Nishina T, Satoh T, Kawakami H, Yamaguchi K, Ohtsubo K, Kato T, Horita Y, Tsuji A, Yasui H, Goto M, Hamamoto Y, Wakabayashi M, Ikeno T, Shitara K, Bando H, Tsuchihara K, Miki I, Ichiki H, Ohtsu A, **Yoshino T**. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. ***JCO Precis Oncol.*** 2023 Mar;7:e2200653. doi: 10.1200/PO.22.00653. PMID: 36996376. (**Corresponding author**)

171. Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, **Yoshino T**. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ***Br J Cancer.*** 2023 Mar 4. doi: 10.1038/s41416-023-02212-2. Epub ahead of print. PMID: 36871043. (**Corresponding author**)

172. Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, **Yoshino T**, Tsuchihara K. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. ***Int J Clin Oncol.*** 2023 Mar 1. doi: 10.1007/s10147-023-02318-w. Epub ahead of print. PMID: 36856908.

173. Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, **Yoshino T**, Ikeda M, Morizane C. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. ***Br J Cancer.*** 2023 Feb 13. doi: 10.1038/s41416-023-02189-y. Epub ahead of print. PMID: 36782009.

174. Van Cutsem E, Taieb J, Yaeger R, **Yoshino T**, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, André T, Carrière Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and

Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. ***J Clin Oncol.*** 2023 Feb 10:JCO2201693. doi: 10.1200/JCO.22.01693. Epub ahead of print. PMID: 36763936.

175. Yoshino T, Taieb J, Kuboki Y, Pfeiffer P, Kumar A, Hochster HS. Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. ***Ther Adv Med Oncol.*** 2023 Jan 21;15:17588359221146137. doi: 10.1177/17588359221146137. PMID: 36743525; PMCID: PMC9893398. **(First and Corresponding author)**

176. Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, Subbiah V, Westphalen BC, Lawler M, Park K, Perdomo S, Yoshino T, Wu J, Biankin AV; Lancet Oncology Commission on Cancer Omics and Precision Oncology. Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. ***Lancet Oncol.*** 2023 Feb;24(2):123-125. doi: 10.1016/S1470-2045(23)00007-4. PMID: 36725142.

177. Koppikar S, Oaknin A, Babu KG, Lorusso D, Gupta S, Wu LY, Rajabto W, Harano K, Hong SH, Malik RA, Strebel H, Aggarwal IM, Lai CH, Dejthevaporn T, Tangjitgamol S, Cheng WF, Chay WY, Benavides D, Hashim NM, Moon YW, Yunokawa M, Anggraeni TD, Wei W, Curigliano G, Maheshwari A, Mahantshetty U, Sheshadri S, Peters S, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer. ***ESMO Open.*** 2023 Jan 23;8(1):100774. doi: 10.1016/j.esmoop.2022.100774. Epub ahead of print. PMID: 36696825.

178. Bando H, Ohtsu A, Yoshino T. Therapeutic landscape and future direction of metastatic colorectal cancer. ***Nat Rev Gastroenterol Hepatol.*** 2023 Jan 20. doi: 10.1038/s41575-022-00736-1. Epub ahead of print. PMID: 36670267. **(Corresponding author)**

179. Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. ***Nat Med.*** 2023 Jan 16. doi: 10.1038/s41591-022-02115-4. Epub ahead of print. PMID: 36646802.

180. Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ***ESMO Open.*** 2023 Jan 5;8(1):100762. doi:

10.1016/j.esmoop.2022.100762. Epub ahead of print. PMID: 36610262.

181. Kotani D, Nakamura Y, Fujisawa T, Bando H, Sakamoto N, Johns AL, Park K; ICGC-ARGO; Casolino R, **Yoshino T**, Biankin AV. ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer. ***Lancet Oncol.*** 2023 Jan;24(1):20-21. doi: 10.1016/S1470-2045(22)00650-7. PMID: 36603918. **(Corresponding author)**

182. Sato S, Nakamura Y, Oki E, **Yoshino T**. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan. ***Clin Colorectal Cancer.*** 2022 Dec 8:S1533-0028(22)00133-5. doi: 10.1016/j.clcc.2022.12.001. Epub ahead of print. PMID: 36567192.

183. Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, **Yoshino T**, Saji S, Matsuda F. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population. ***Cancer Med.*** 2022 Dec 16. doi: 10.1002/cam4.5541. Epub ahead of print. PMID: 36524458.

184. Shah MA, **Yoshino T**, Tebbutt NC, Grothey A, Tabernero J, Xu RH, Cervantes A, Oh SC, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu VK, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. ***Clin Colorectal Cancer.*** 2022 Nov 11:S1533-0028(22)00125-6. doi: 10.1016/j.clcc.2022.11.002. Epub ahead of print. PMID: 36503738.

185. Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, **Yoshino T**, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. ***BMC Cancer.*** 2022 Dec 9;22(1):1292. doi: 10.1186/s12885-022-10398-6. PMID: 36494792.

186. Naito Y, Sunami K, Kage H, Komine K, Amano T, Imai M, Koyama T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Watanabe K, Shirota H, Kinoshita I, Yoshioka M, Mamesaya N, Ito M, Kohsaka S, Saigusa Y, Yamamoto K, Hirata M, Tsuchihara K, **Yoshino T**. Concordance Between Recommendations From

Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan. ***JAMA Netw Open.*** 2022 Dec 1;5(12):e2245081. doi: 10.1001/jamanetworkopen.2022.45081. PMID: 36469316. **(Corresponding author)**

187. Van Cutsem E, Hochster H, Shitara K, Mayer R, Ohtsu A, Falcone A, **Yoshino T**, Doi T, Ilson DH, Arkenau HT, George B, Benhadji KA, Makris L, Tabernero J. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. ***ESMO Open.*** 2022 Nov 28;7(6):100633. doi: 10.1016/j.esmoop.2022.100633. Epub ahead of print. PMID: 36455504.
188. Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, **Yoshino T**, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. ***Eur J Cancer.*** 2022 Nov 2;178:162-170. doi: 10.1016/j.ejca.2022.10.022. Epub ahead of print. PMID: 36446161.
189. Vaghi C, Mauri G, Agostara AG, Patelli G, Pizzutilo EG, Nakamura Y, **Yoshino T**, Siena S, Sartore-Bianchi A. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. ***Cancer Treat Rev.*** 2022 Nov 11;112:102488. doi: 10.1016/j.ctrv.2022.102488. Epub ahead of print. PMID: 36410093.
190. Sakamoto Y, Bando H, Nakamura Y, Hasegawa H, Kuwaki T, Okamoto W, Taniguchi H, Aoyagi Y, Miki I, Uchigata H, Kuramoto N, Fuse N, **Yoshino T**, Ohtsu A. Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. ***Clin Colorectal Cancer.*** 2022 Oct 22:S1533-0028(22)00107-4. doi: 10.1016/j.clcc.2022.10.003. Epub ahead of print. PMID: 36376197.
191. **Yoshino T**, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Le DT, Adachi N, Fogelman D, Marinello P, Diaz LA Jr. Pembrolizumab in Asian patients with microsatellite-instability-high / mismatch-repair-deficient colorectal cancer. ***Cancer Sci.*** 2022 Nov 12. doi: 10.1111/cas.15650. Epub ahead of print. PMID: 36369901. **(First and Corresponding author)**
192. Sakata H, Murase M, Kato T, Yamaguchi K, Sugihara K, Suzuki S, **Yoshino T**. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal

cancer: an early post-marketing phase vigilance study. ***Int J Clin Oncol.*** 2022 Nov 10. doi: 10.1007/s10147-022-02264-z. Epub ahead of print. PMID: 36355316.

193. Watanabe J, Terazawa T, Yamane S, Kazama H, Uetake H, **Yoshino T**. Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. ***Int J Clin Oncol.*** 2022 Oct 28. doi: 10.1007/s10147-022-02259-w. Epub ahead of print. PMID: 36307632. **(Corresponding author)**

194. Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, **Yoshino T**, Martinelli E; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. ***Ann Oncol.*** 2022 Oct 19:S0923-7534(22)04192-8. doi: 10.1016/j.annonc.2022.10.003. Epub ahead of print. PMID: 36307056.

195. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, **Yoshino T**, Meyerhardt JA, André T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. ***J Clin Oncol.*** 2022 Oct 28:JCO2102726. doi: 10.1200/JCO.21.02726. Epub ahead of print. PMID: 36306483.

196. Krebs MG, Malapelle U, André F, Paz-Ares L, Schuler M, Thomas DM, Vainer G, **Yoshino T**, Rolfo C. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. ***JAMA Oncol.*** 2022 Oct 20. doi: 10.1001/jamaoncol.2022.4457. Epub ahead of print. PMID: 36264554.

197. Sakai SA, Aoshima M, Sawada K, Horasawa S, Yoshikawa A, Fujisawa T, Kadowaki S, Denda T, Matsuhashi N, Yasui H, Goto M, Yamazaki K, Komatsu Y, Nakanishi R, Nakamura Y, Bando H, Hamaya Y, Kageyama SI, **Yoshino T**, Tsuchihara K, Yamashita R. Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities. ***Front Cell Infect Microbiol.*** 2022 Sep 14;12:925444. doi: 10.3389/fcimb.2022.925444. PMID: 36189350; PMCID: PMC9515963.

198. Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Hirohashi Y, Furuhata T, Takemasa I, Patel P, Vora H, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, **Yoshino T**, Taniguchi H, Bifulco C, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert CI, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang J, Bavi

P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson E, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Marliot F, Fredriksen T, Buttard B, Lafontaine L, Maby P, Majdi A, Hijazi A, El Sissy C, Kirilovsky A, Berger A, Lagorce C, Paustian C, Ballesteros-Merino C, Dijkstra J, Van de Water C, van Lent-van Vliet S, Knijn N, Muşină AM, Scripcariu DV, Marincola FM, Ascierto PA, Fox BA, Pagès F, Kawakami Y, Galon J. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. ***Cancers (Basel).*** 2022 Sep 6;14(18):4346. doi: 10.3390/cancers14184346. PMID: 36139506.

199. Franko J, Yin J, Adams RA, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg RM, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, **Yoshino T**, de Gramont A, Shi Q; ARCAD collaborators. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. ***Eur J Cancer.*** 2022 Aug 19;174:142-152. doi: 10.1016/j.ejca.2022.07.021. Epub ahead of print. PMID: 35994794.
200. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, **Yoshino T**, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. ***JCO Precis Oncol.*** 2022 Aug;6:e2200107. doi: 10.1200/PO.22.00107. PMID: 35977349.
201. Sunami K, Naito Y, Komine K, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, Saigusa Y, **Yoshino T.** Chronological improvement in precision oncology implementation in Japan. ***Cancer Sci.*** 2022 Aug 17. doi: 10.1111/cas.15517. Epub ahead of print. PMID: 35976133. **(Corresponding author)**
202. Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, Mizukami T, Moriwaki T, Ohtsubo K, Komoda M, Mitani S, Nagashima F, Kato K, Yamada T, Hasegawa H, Yamazaki K, **Yoshino T**, Hyodo I. Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer. ***JCO Precis Oncol.*** 2022 Aug;6:e2200135. doi:

10.1200/PO.22.00135. PMID: 35952320.

203. Ikeda M, Uetake H, **Yoshino T**, Hata T, Oba MS, Takita A, Kimura T. Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer-VTE Registry). ***Cancer Sci.*** 2022 Aug 10. doi: 10.1111/cas.15527. Epub ahead of print. PMID: 35947508.

204. Milella M, Lawlor RT, Luchini C, Johns AL; ICGC-ARGO, Casolino R, **Yoshino T**, Biankin AV, Scarpa A. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. ***Lancet Oncol.*** 2022 Aug;23(8):991-992. doi: 10.1016/S1470-2045(22)00448-X. PMID: 35901820.

205. Ito R, Nakamura Y, Sunakawa H, Fujiwara H, Hojo H, Nakamura N, Fujita T, Yano T, Daiko H, Akimoto T, **Yoshino T**, Kojima T. Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ***Esophagus.*** 2022 Jul 28. doi: 10.1007/s10388-022-00936-3. Epub ahead of print. PMID: 35900683.

206. Imai M, Nakamura Y, Sunami K, Kage H, Komine K, Koyama T, Amano T, Ennishi D, Kanai M, Kenmotsu H, Maeda T, Morita S, Sakai D, Bando H, Makiyama A, Suzuki T, Hirata M, Kohsaka S, Tsuchihara K, Naito Y, **Yoshino T**. Expert Panel Consensus Recommendations on the Use of Circulating Tumor DNA Assays for Patients with Advanced Solid Tumors. ***Cancer Sci.*** 2022 Jul 25. doi: 10.1111/cas.15504. Epub ahead of print. PMID: 35876224.

207. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, **Yoshino T,** Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. ***Ann Oncol.*** 2022 Jun 9:S0923-7534(22)01721-5. doi: 10.1016/j.annonc.2022.05.520. Epub ahead of print. PMID: 35809752.

208. Kanesvaran R, Castro E, Wong A, Fizazi K, Chua MLK, Zhu Y, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Prabhash K, Zou Q, Curigliano G, Poon E, Choo SP, Peters S, Lim E, **Yoshino T**, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ***ESMO Open.*** 2022 Jul 4;7(4):100518. doi: 10.1016/j.esmoop.2022.100518. Epub ahead of print. PMID: 35797737.

209. Aoki Y, Kawazoe A, Kubota Y, Chida K, Mishima S, Kotani D, Nakamura Y, Kuboki

Y, Bando H, Kojima T, Doi T, **Yoshino T**, Kuwata T, Shitara K. Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. ***Int J Clin Oncol.*** 2022 Jun 17. doi: 10.1007/s10147-022-02200-1. Epub ahead of print. PMID: 35713753.

210. **Yoshino T**, Van Cutsem E, Li J, Shen L, Kim TW, Sriuranpong V, Xuereb L, Aubel P, Fougeray R, Cattan V, Amellal N, Ohtsu A, Mayer RJ. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ***ESMO Open.*** 2022 Jun 7;7(3):100511. doi: 10.1016/j.esmoop.2022.100511. Epub ahead of print. PMID: 35688062. **(First and Corresponding author)**

211. Yukami H, Kawazoe A, Lin YT, Koyama S, Fukuoka S, Hara H, Takahashi N, Kojima T, Asayama M, Yoshii T, Bando H, Kotani D, Nakamura Y, Kuboki Y, Mishima S, Wakabayashi M, Kuwata T, Goto M, Higuchi K, **Yoshino T**, Doi T, Nishikawa H, Shitara K. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for advanced gastric cancer patients with or without liver metastases in clinical trials. ***Clin Cancer Res.*** 2022 Jun 9:clincanres.0630.2022-2-27 11:45:33.693. doi: 10.1158/1078-0432.CCR-22-0630. Epub ahead of print. PMID: 35679062.

212. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, **Yoshino T**, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ***ESMO Open.*** 2022 May 30;7(3):100477. doi: 10.1016/j.esmoop.2022.100477. Epub ahead of print. PMID: 35653981.

213. Kajiwara T, Nishina T, Nakasya A, Yamashita N, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Moriwaki T, Denda T, Ohtsubo K, Sunakawa Y, Horita Y, Kawakami H, Kato T, Satoh T, Ando K, Mizutani T, Yasui H, Goto M, Okuyama H, Yamazaki K, **Yoshino T**, Hyodo I. NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). ***J Cancer Res Clin Oncol.*** 2022 May 27. doi: 10.1007/s00432-022-04064-4. Epub ahead of print. PMID: 35622165.

214. Nakamura Y, Olsen S, Zhang N, Liao J, **Yoshino T**. Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic

Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database. ***Curr Oncol.*** 2022 May 9;29(5):3433-3448. doi: 10.3390/curroncol29050277. PMID: 35621667.

215. McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll HJ, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, **Yoshino T**, Chibaudel B, deGramont A, Shi Q, Lichtman SM. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. ***JNCI Cancer Spectr.*** 2022 Mar 2;6(2):pkac014. doi: 10.1093/jncics/pkac014. PMID: 35603849.

216. Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, Kagawa Y, Denda T, Satoh T, Yamazaki K, Sunakawa Y, Kato T, Goto M, Yuki S, Nishina T, Oki E, Shinozaki E, Matsuhashi N, Takahashi N, Tsuji A, Ohtsubo K, Wakabayashi M, Ikeno T, Hata M, Odegaard JI, **Yoshino T**. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. ***JCO Precis Oncol.*** 2022 Apr;6:e2100535. doi: 10.1200/PO.21.00535. PMID: 35544728. **(Corresponding author)**

217. Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Yamamoto Y, Shiozawa M, Oki E, Okamoto W, **Yoshino T**, Eguchi Nakajima T. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. ***Target Oncol.*** 2022 May 7. doi: 10.1007/s11523-022-00880-3. Epub ahead of print. PMID: 35524872.

218. **Yoshino T**, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial. ***J Clin Oncol.*** 2022 May 5:JCO2102628. doi: 10.1200/JCO.21.02628. Epub ahead of print. PMID: 35512259. **(First and Corresponding author)**

219. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, **Yoshino T**, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive

unresectable or recurrent biliary tract cancer: HERB trial. ***Future Oncol.*** 2022 May 5. doi: 10.2217/fon-2022-0214. Epub ahead of print. PMID: 35510484.

220. Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, **Yoshino T,** Zhong WY, Fogelman D, Marinello P, Andre T; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. ***Lancet Oncol.*** 2022 Apr 12:S1470-2045(22)00197-8. doi: 10.1016/S1470-2045(22)00197-8. Epub ahead of print. PMID: 35427471.

221. Marshall JL, Peshkin BN, **Yoshino T**, Vowinckel J, Danielsen HE, Melino G, Tsamardinos I, Haudenschild C, Kerr DJ, Sampaio C, Rha SY, FitzGerald KT, Holland EC, Gallagher D, Garcia-Foncillas J, Juhl H. The Essentials of Multiomics. ***Oncologist.*** 2022 Apr 5;27(4):272-284. doi: 10.1093/oncolo/oyab048. PMID: 35380712.

222. Fujii S, Kotani D, Hattori M, Nishihara M, Shikanai T, Hashimoto J, Hama Y, Nishino T, Suzuki M, Yoshidumi A, Ueno M, Komatsu Y, Masuishi T, Hara H, Esaki T, Nakamura Y, Bando H, Yamada T, **Yoshino T**. Rapid screening using pathomorphological interpretation to detect BRAFV600E mutation and microsatellite instability in colorectal cancer. ***Clin Cancer Res.*** 2022 Apr 1:clincanres.4391.2021. doi: 10.1158/1078-0432.CCR-21-4391. Epub ahead of print. PMID: 35363302.

223. Kotani D, Nakamura Y, Fujisawa T, Bando H, Sakamoto N, Johns AL, Park K; ICGC-ARGO, Casolino R, **Yoshino T**, Biankin AV. ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. ***Lancet Oncol.*** 2022 Apr;23(4):463-464. doi: 10.1016/S1470-2045(22)00142-5. PMID: 35358454. **(Corresponding author)**

224. Maron SB, Moya S, Morano F, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, **Yoshino T**, Shitara K, Nakamura Y, Saeed A, Kasi P, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, Pietrantonio F, Klempner SJ, Catenacci DVT. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. ***J Clin Oncol.*** 2022 Mar 29:JCO2102453. doi: 10.1200/JCO.21.02453. Epub ahead of print. PMID: 35349370.

225. Yothers G, Venook AP, Oki E, Niedzwiecki D, Lin Y, Crager MR, Chao C, Baehner

FL, Wolmark N, **Yoshino T**. Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin. ***J Gastrointest Oncol.*** 2022 Feb;13(1):126-136. doi: 10.21037/jgo-21-620. PMID: 35284101; PMCID: PMC8899729.

226. Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, Kalashnikova E, Sharma S, Malhotra M, Demko ZP, Aleshin A, Rodriguez A, Billings PR, Grothey A, Taieb J, Cunningham D, **Yoshino T**, Kopetz S. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. ***JCO Precis Oncol.*** 2022 Mar;6:e2100181. doi: 10.1200/PO.21.00181. PMID: 35263168.

227. Chida K, Kawazoe A, Suzuki T, Kawazu M, Ueno T, Takenouchi K, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Kuwata T, Sakamoto N, Watanabe J, Mano H, Ikeda M, Shitara K, Endo I, Nakatsura T, **Yoshino T**. Transcriptomic profiling of MSI-H/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy. ***Clin Cancer Res.*** 2022 Mar 7:clincanres.0041.2022. doi: 10.1158/1078-0432.CCR-22-0041. Epub ahead of print. PMID: 35254400.

228. Strickler JH, **Yoshino T**, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. ***JAMA Oncol.*** 2022 Mar 3. doi: 10.1001/jamaoncol.2021.8196. Epub ahead of print. PMID: 35238866.

229. Matsumura M, Hasegawa K, Oba M, Yamaguchi K, Uetake H, **Yoshino T**, Morita S, Takahashi K, Unno M, Shimada Y, Muro K, Matsuhashi N, Mori M, Baba H, Shimada M, Mise Y, Kawaguchi Y, Kagimura T, Ishigure K, Saiura A, Sugihara K, Kokudo N. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. ***Langenbecks Arch Surg.*** 2022 Feb 25. doi: 10.1007/s00423-022-02434-7. Epub ahead of print. PMID: 35211831.

230. Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsuhashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, **Yoshino T**. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. ***JCO Precis Oncol.*** 2022 Feb;6:e2100383. doi:

10.1200/PO.21.00383. PMID: 35188805.

231. Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, **Yoshino T**. Preoperative Chemoradiotherapy Plus Nivolumab Before Surgery in Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer Patients. ***Clin Cancer Res.*** 2022 Jan 21:clincanres.3213.2021. doi: 10.1158/1078-0432.CCR-21-3213. Epub ahead of print. PMID: 35063964. **(Corresponding author)**

232. Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, **Yoshino T**, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. ***Eur J Cancer.*** 2022 Jan 13;163:1-15. doi: 10.1016/j.ejca.2021.12.007. Epub ahead of print. PMID: 35033994.

233. Milella M, Luchini C, Lawlor RT, Johns AL, Casolino R, **Yoshino T,** Biankin AV; ICGC-ARGO. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. ***Lancet Oncol.*** 2022 Jan;23(1):25-26. doi: 10.1016/S1470-2045(21)00703-8. PMID: 34973218.

234. Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, **Yoshino T**, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ***ESMO Open.*** 2021 Dec 9;6(6):100328. doi: 10.1016/j.esmoop.2021.100328. Epub ahead of print. PMID: 34896698.

235. Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, André T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, **Yoshino T**, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. ***J Natl Cancer Inst.*** 2021 Dec 4:djab218. doi: 10.1093/jnci/djab218. Epub ahead of print. PMID: 34865086.

236. Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, **Yoshino T**,

Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ***ESMO Open.*** 2021 Dec 1;6(6):100304. doi: 10.1016/j.esmoop.2021.100304. Epub ahead of print. PMID: 34864348.

237. Keam B, Machiels JP, Kim HR, Licitra L, Golusinski W, Gregoire V, Lee YG, Belka C, Guo Y, Rajappa SJ, Tahara M, Azrif M, Ang MK, Yang MH, Wang CH, Ng QS, Wan Zamaniah WI, Kiyota N, Babu S, Yang K, Curigliano G, Peters S, Kim TW, **Yoshino T**, Pentheroudakis G. Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ***ESMO Open.*** 2021 Nov 26;6(6):100309. doi: 10.1016/j.esmoop.2021.100309. Epub ahead of print. PMID: 34844180.

238. Miyo M, Kato T, Nakamura Y, Taniguchi H, Takahashi Y, Ishii M, Okita K, Ando K, Yukami H, Mishima S, Yamazaki K, Kotaka M, Watanabe J, Oba K, Aleshin A, Billings PR, Rabinowitz M, Kotani D, Oki E, Takemasa I, Mori M, **Yoshino T**. DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. ***Cancer Sci.*** 2021 Nov 27. doi: 10.1111/cas.15226. Epub ahead of print. PMID: 34839585.

239. Kim TW, Taieb J, Gurary EB, Lerman N, Cui K, **Yoshino T**. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. ***Future Oncol.*** 2021 Nov 15. doi: 10.2217/fon-2021-0899. Epub ahead of print. PMID: 34779646.

240. Bando H, Tsukada Y, Ito M, **Yoshino T**. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. ***Clin Colorectal Cancer.*** 2021 Oct 16:S1533-0028(21)00099-2. doi: 10.1016/j.clcc.2021.10.001. Epub ahead of print. PMID: 34776358.

241. Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, **Yoshino T**. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. ***Nat Med.*** 2021 Nov 11. doi: 10.1038/s41591-021-01553-w. Epub ahead of print. PMID: 34764486. **(Corresponding author)**

242. Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, **Yoshino T**, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E,

Georgoulias V, Ben-Aharon I, Shi Q. Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. ***J Clin Oncol.*** 2021 Nov 9:JCO2102008. doi: 10.1200/JCO.21.02008. Epub ahead of print. PMID: 34752136.

243. Yoshino T. COLOMATE challenge to overcome resistance in metastatic colorectal cancer. ***Oncology*** (Williston Park). 2021 Oct 21;35(10):656. doi: 10.46883/ONC.2021.3510.0656. PMID: 34677923. **(First and Corresponding author)**

244. Hatanaka Y, Kuwata T, Morii E, Kanai Y, Ichikawa H, Kubo T, Hatanaka KC, Sakai K, Nishio K, Fujii S, Okamoto W, Yoshino T, Ochiai A, Oda Y. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. ***Pathol Int.*** 2021 Oct 6. doi: 10.1111/pin.13170. Epub ahead of print. PMID: 34614280.

245. Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ***Esophagus.*** 2021 Oct 5. doi: 10.1007/s10388-021-00885-3. Epub ahead of print. PMID: 34611830.

246. Yoshino T. The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer-From "MAYBE" to "MUST BE". ***Oncology*** (Williston Park). 2021 Sep 22;45(9):554. doi: 10.46883/ONC.2021.3509.0554. PMID: 34550665. **(First and Corresponding author)**

247. Kobayashi S, Takahashi S, Nomura S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N, Taniguchi H, Yoshino T. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. ***Cancer Med.*** 2021 Sep 18. doi: 10.1002/cam4.4227. Epub ahead of print. PMID: 34535965. (**Corresponding author**)

248. Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, De Gramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. ***J Natl Cancer*** Inst. 2021 Sep 10:djab187. doi: 10.1093/jnci/djab187. Epub ahead of print. PMID: 34505880.

249. Nakamura Y, Fujisawa T, Taniguchi H, Bando H, Okamoto W, Tsuchihara K, Yoshino T, Ohtsu A. SCRUM-Japan GI- and MONSTAR-SCREEN: Path to Realization of Biomarker-Guided Precision Oncology in Advanced Solid Tumors.

Cancer Sci. 2021 Sep 12. doi: 10.1111/cas.15132. Epub ahead of print. PMID: 34510657. **(Corresponding author)**

250. Okuyama H, Kagawa Y, Masuishi T, Mishima S, Shirasu H, Ando K, Yuki S, Muro K, **Yoshino T**, Yamazaki K, Oki E, Komatsu Y, Tsuji A. Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. *Int J Clin Oncol.* 2021 Sep 2. doi: 10.1007/s10147-021-02004-9. Epub ahead of print. PMID: 34476649.

251. Oki E, Ando K, Taniguchi H, **Yoshino T**, Mori M. Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. *Ann Gastroenterol Surg.* 2021 Sep 9;6(1):37-45. doi: 10.1002/ags3.12503. PMID: 35106413; PMCID: PMC8786685.

252. **Yoshino T**, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. *Ann Oncol.* 2021 Aug 16:S0923-7534(21)03982-X. doi: 10.1016/j.annonc.2021.08.1752. Epub ahead of print. PMID: 34411693. **(First and Corresponding author)**

253. Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, **Yoshino T**, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. *J Natl Cancer Inst.* 2021 Aug 18:djab123. doi: 10.1093/jnci/djab123. Epub ahead of print. PMID: 34405233.

254. Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, **Yoshino T**, Saji S, Matsuda F. Large-Scale Prospective Genome-Wide Association Study of Oxaliplatin in Stage II/III Colon Cancer and Neuropathy. *Ann Oncol.* 2021 Aug 12:S0923-7534(21)03974-0. doi: 10.1016/j.annonc.2021.08.1745. Epub ahead of print. PMID: 34391895.

255. Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, Terazawa T, Satoh T, Shinozaki E, Nishina T, Sunakawa Y, Komatsu Y, Hara H, Oki E, Matsuhashi N, Ohta T, Kato T, Ohtsubo K, Kawakami T, Okano N, Yamamoto Y, Yamada T, Tsuji A,

Odegaard JI, Taniguchi H, Doi T, Fujii S, **Yoshino T**. Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. ***Clin Cancer Res.*** 2021 Aug 10:clincanres.1414.2021. doi: 10.1158/1078-0432.CCR-21-1414. Epub ahead of print. PMID: 34376535.

256. Taniguchi H, Masuishi T, Kawazoe A, Muro K, Kadowaki S, Bando H, Iino S, Kageyama R, **Yoshino T**. Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer. ***Int J Clin Oncol.*** 2021 Jul 21. doi: 10.1007/s10147-021-01987-9. Epub ahead of print. PMID: 34291369.

257. Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, **Yoshino T**, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. ***Ther Adv Med Oncol.*** 2021 Jun 30;13:17588359211020547. doi: 10.1177/17588359211020547. PMID: 34262614; PMCID: PMC8252342.

258. Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, **Yoshino T**. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. ***Oncologist.*** 2021 Jul 7. doi: 10.1002/onco.13870. Epub ahead of print. PMID: 34232546.

259. Taniguchi H, **Yoshino T,** Yamaguchi K, Yamazaki K, Nixon AB, Tabernero J, Van Cutsem E, Robling KR, Abada PB, Hozak RR, Siegel R, Fill JA, Wijayawardana S, Walgren RA, Giles B, Jones A, Pitts KR, Drove N, Muro K. Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. ***Curr Med Res Opin.*** 2021 Jul 7:1. doi: 10.1080/03007995.2021.1940908. Epub ahead of print. PMID: 34229554.

260. Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, **Yoshino T**, Ohta T, Taniguchi H, Kagawa Y. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.

BMC Cancer. 2021 Jun 7;21(1):674. doi: 10.1186/s12885-021-08395-2. PMID: 34098908.

261. Toshida K, Itoh S, Yoshizumi T, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Oki E, Nakamura Y, **Yoshino T**, Mori M. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report. *Clin J Gastroenterol.* 2021 Jun 3. doi: 10.1007/s12328-021-01458-8. Epub ahead of print. PMID: 34085164.

262. Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, **Yoshino T**, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. *J Natl Cancer Inst.* 2021 Jun 1:djab112. doi: 10.1093/jnci/djab112. Epub ahead of print. PMID: 34061178.

263. Kotani D, **Yoshino T**, Kotaka M, Kawazoe A, Masuishi T, Taniguchi H, Yamazaki K, Yamanaka T, Oki E, Muro K, Komatsu Y, Bando H, Satake H, Kato T, Tsuji A. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. *Invest New Drugs.* 2021 May 21. doi: 10.1007/s10637-021-01125-2. Epub ahead of print. PMID: 34019214.

264. Glimelius B, Stintzing S, Marshall J, **Yoshino T**, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. *Cancer Treat Rev.* 2021 May 4;98:102218. doi: 10.1016/j.ctrv.2021.102218. Epub ahead of print. PMID: 34015686.

265. Aoki H, Ueha S, Nakamura Y, Shichino S, Nakajima H, Shimomura M, Sato A, Nakatsura T, **Yoshino T**, Matsushima K. Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. *Cancer Sci.* 2021 May 20. doi: 10.1111/cas.14975. Epub ahead of print. PMID: 34014607.

266. Dasari A, Sobrero A, Yao J, **Yoshino T**, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. *Future Oncol.* 2021 May 17. doi: 10.2217/fon-2021-0202. Epub ahead of print. PMID: 33993740.

267. Oki E, Watanabe J, Sato T, Kagawa Y, Kuboki Y, Ikeda M, Ueno H, Kato T, Kusumoto T, Masuishi T, Yamaguchi K, Kanazawa A, Nishina T, Uetake H, Yamanaka T, **Yoshino T**. Impact of the 12-gene recurrence score assay on deciding

adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study. ***ESMO Open.*** 2021 May 10;6(3):100146. doi: 10.1016/j.esmoop.2021.100146. Epub ahead of print. PMID: 33984677.

268. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, **Yoshino T**; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. ***Lancet Oncol.*** 2021 May 4:S1470-2045(21)00086-3. doi: 10.1016/S1470-2045(21)00086-3. Epub ahead of print. PMID: 33961795. **(Corresponding author)**

269. Chida K, Kotani D, Nakamura Y, Kawazoe A, Kuboki Y, Shitara K, Kojima T, Taniguchi H, Watanabe J, Endo I, **Yoshino T**. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. ***Ther Adv Med Oncol.*** 2021 Apr 20;13:17588359211009143. doi: 10.1177/17588359211009143. PMID: 33959196; PMCID: PMC8064512.

270. Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, Bllings PR, Rabinowitz M, Oki E, Takemasa I, Kato T, Mori M, **Yoshino T**. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. ***Cancer Sci.*** 2021 May 1. doi: 10.1111/cas.14926. Epub ahead of print. PMID: 33931919.

271. Kato T, Kagawa Y, Kuboki Y, Gamoh M, Komatsu Y, Yasui H, Satake H, Oki E, Tanioka H, Kotaka M, Makiyama A, Denda T, Goto M, **Yoshino T**, Yamazaki K, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. ***Int J Clin Oncol.*** 2021 Apr 29. doi: 10.1007/s10147-021-01902-2. Epub ahead of print. PMID: 33928486.

272. Chida K, Kawazoe A, Kawazu M, Suzuki T, Nakamura Y, Nakatsura T, Kuwata T, Ueno T, Kuboki Y, Kotani D, Kojima T, Taniguchi H, Mano H, Ikeda M, Shitara K, Endo I, **Yoshino T**. A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/ dMMR gastrointestinal tumors. ***Clin Cancer Res.*** 2021 Apr 29:clincanres.0401.2021. doi: 10.1158/1078-0432.CCR-21-0401. Epub ahead of print. PMID: 33926917.

273. Ishii T, Suzuki A, Kuwata T, Hisamitsu S, Hashimoto H, Ohara Y, Yanagihara K, Mitsunaga S, **Yoshino T**, Kinoshita T, Ochiai A, Shitara K, Ishii G. Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy. ***Gastric Cancer.*** 2021 Apr 9. doi: 10.1007/s10120-021-01174-9. Epub ahead of print. PMID: 33837489.

274. Sunami K, Naito Y, Aimono E, Amano T, Ennishi D, Kage H, Kanai M, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, **Yoshino T**. Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. Int J Clin Oncol. 2021 Mar 30. doi: 10.1007/s10147-021-01897-w. Epub ahead of print. Erratum for: ***Int J Clin Oncol.*** 2021 Mar;26(3):443-449. PMID: 33786712. (**Corresponding author**)

275. Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, **Yoshino T**, Yoshida K, Maehara Y. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ***ESMO Open.*** 2021 Mar 18;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub ahead of print. PMID: 33744811.

276. Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, Van Cutsem E, Venook A, Douillard JY, Heinemann V, Punt CJA, Falcone A, Bokemeyer C, Kaplan R, Lenz HJ, Koopman M, **Yoshino T**, Zalcberg J, Grothey A, de Gramont A, Shi Q, André T. BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. ***J Natl Cancer Inst.*** 2021 Mar 18:djab042. doi: 10.1093/jnci/djab042. Epub ahead of print. PMID: 33734401.

277. Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, **Yoshino T**, Van Cutsem E, Yang P, Farooqui M, Le DT. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. ***Lancet Oncol.*** 2021 Apr 1:S1470-2045(21)00064-4. doi: 10.1016/S1470-2045(21)00064-4. Epub ahead of print. PMID: 33812497.

278. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, **Yoshino T**, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. ***J Clin Oncol.*** 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. PMID: 33503393.

279. Kagawa Y, Fernandez EE, García-Foncillas J, Bando H, Taniguchi H, Vivancos A, Akagi K, Garcia A, Denda T, Ros J, Nishina T, Baraibar I, Komatsu Y, Ciardiello D, Oki E, Kudo T, Kato T, Yamanaka T, Tabernero J, **Yoshino T**. Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. ***Clin Cancer Res.*** 2021 Feb 18:clincanres.3677.2020. doi: 10.1158/1078-0432.CCR-20-3677. Epub ahead of print. PMID: 33602686. (**Corresponding author**)

280. **Yoshino T**, Uetake H, Funato Y, Yamaguchi Y, Koyama T, Ozawa D, Tajiri M, Muro K. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. ***Jpn J Clin Oncol.*** 2021 Jan 13:hyaa243. doi: 10.1093/jjco/hyaa243. Epub ahead of print. PMID: 33438718.

281. Iveson TJ, Sobrero AF, **Yoshino T**, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, Yamanaka T, Boukovinas I, Hollander NH, Galli F, Yamazaki K, Georgoulias V, Kerr R, Oki E, Lonardi S, Harkin A, Rosati G, Paul J. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. ***J Clin Oncol.*** 2021 Jan 13:JCO2001330. doi: 10.1200/JCO.20.01330. Epub ahead of print. PMID: 33439695.

282. Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T, **Yoshino T**. The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. ***Cancer Sci.*** 2021 Jan 6. doi: 10.1111/cas.14798. Epub ahead of print. PMID: 33403729.

283. Kobayashi S, Nakamura Y, Takahashi S, Taniguchi H, **Yoshino T**. ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve "Precision Onco-Surgery" in Resectable Colorectal Liver Metastases. ***Ann Surg Oncol.*** 2021 Jan 4. doi: 10.1245/s10434-020-09456-9. Epub ahead of print. PMID: 33398645. (**Corresponding author**)

284. Kobayashi S, Nakamura Y, Taniguchi H, Odegaard JI, Nomura S, Kojima M, Sugimoto M, Konishi M, Gotohda N, Takahashi S, **Yoshino T**. Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases. ***Ann Surg Oncol.*** 2021 Jan 3. doi: 10.1245/s10434-020-09449-8. Epub ahead of print. PMID: 33393041.

(**Corresponding author**)

285. Sunami K, Naito Y, Aimono E, Amano T, Ennishi D, Kage H, Kanai M, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Kohsaka S, Tsuchihara K, **Yoshino T**. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. ***Int J Clin Oncol.*** 2021 Jan 1. doi: 10.1007/s10147-020-01844-1. Epub ahead of print. PMID: 33385275. (**Corresponding author**)

286. Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, **Yoshino T**, Tsuchihara K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). ***Int J Clin Oncol.*** 2020 Nov 29. doi: 10.1007/s10147-020-01831-6. Epub ahead of print. PMID: 33249514.

287. Yagisawa M, Sawada K, Nakamura Y, Fujii S, Yuki S, Komatsu Y, **Yoshino T**, Sakamoto N, Taniguchi H. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. ***Clin Colorectal Cancer.*** 2020 Nov 13:S1533-0028(20)30156-0. doi: 10.1016/j.clcc.2020.11.002. Epub ahead of print. PMID: 33384243.

288. Okunaka M, Kotani D, Demachi K, Kawazoe A, **Yoshino T**, Kawasaki T, Shitara K. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. ***BMC Cancer.*** 2020 Nov 16;20(1):1111. doi: 10.1186/s12885-020-07614-6. PMID: 33198652.

289. Nakamura Y, Sasaki A, Yukami H, Jogo T, Kawazoe A, Kuboki Y, Taniguchi H, Yamashita R, Kuwata T, Ozawa M, Nakamura M, **Yoshino T**, Shitara K. Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient with EGFR-Amplified Advanced Gastric Cancer Treated with Cetuximab. ***JCO Precision Oncology*** 2020 October 20, 2020: DOI https://ascopubs.org/doi/full/10.1200/PO.20.00263

290. Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T, Fukunaga M, Ueki T, Shitara K, Shinkai H, Tanida N, Oki E, Sunami E, Ohtsu A, Maehara Y, **Yoshino T**. Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon

Cancer: The Randomized Phase 3 ACHIEVE-2 Trial. ***Ann Oncol.*** 2020 Oct 26:S0923-7534(20)42983-7. doi: 10.1016/j.annonc.2020.10.480. Epub **(Corresponding author)**

291. Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, **Yoshino T**. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. ***Cancer Sci.*** 2020 Oct 19. doi: 10.1111/cas.14693. Epub ahead of print. PMID: 33075166.

292. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, **Yoshino T**, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, André T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. ***J Clin Oncol.*** 2020 Dec 23:JCO2001600. doi: 10.1200/JCO.20.01600. Epub ahead of print. PMID: 33356421.

293. Kuwata T, Wakabayashi M, Hatanaka Y, Morii E, Oda Y, Taguchi K, Noguchi M, Ishikawa Y, Nakajima T, Sekine S, Nomura S, Okamoto W, Fujii S, **Yoshino T**; SCRUM-Japan GI-SCREEN Pathology Group. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN. ***Pathol Int.*** 2020 Oct 8. doi: 10.1111/pin.13029. Epub ahead of print. PMID: 33030786.

294. Lenz HJ, Argiles G, **Yoshino T**, Tejpar S, Ciardiello F, Braunger J, Salnikov AV, Gabrielyan O, Schmid R, Höfler J, Kitzing T, Van Cutsem E. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. ***Clin Colorectal Cancer.*** 2020 Sep 15:S1533-0028(20)30127-4. doi: 10.1016/j.clcc.2020.09.003. Epub ahead of print. PMID: 33041226.

295. Izawa N, Shitara K, Yonesaka K, Yamanaka T, **Yoshino T**, Sunakawa Y, Masuishi T, Denda T, Yamazaki K, Moriwaki T, Okuda H, Kondoh C, Nishina T, Makiyama A, Baba H, Yamaguchi H, Nakamura M, Hyodo I, Muro K, Nakajima TE. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). ***Target Oncol.*** 2020 Sep 22. doi: 10.1007/s11523-020-00750-w. Online ahead of print

296. André T, Meyerhardt J, Iveson T, Sobrero A, **Yoshino T,** Souglakos I, Grothey A, Niedzwiecki D, Saunders M, Labianca R, Yamanaka T, Boukovinas I, Vernerey D, Meyers J, Harkin A, Torri V, Oki E, Georgoulias V, Taieb J, Shields A, Shi Q. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. ***Lancet Oncol.*** 2020 Dec;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1. PMID: 33271092.

297. Sobrero AF, Puccini A, Shi Q, Grothey A, Andrè T, Shields AF, Souglakos I, **Yoshino T**, Iveson T, Ceppi M, Bruzzi P. A new prognostic and predictive tool for shared decision making in stage III colon cancer. ***Eur J Cancer.*** 2020 Sep 3;138:182-188. doi: 10.1016/j.ejca.2020.07.031. Online ahead of print

298. Miyo M, Kato T, **Yoshino T**, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. ***BMC Cancer.*** 2020 Jul 23;20(1):687. doi: 10.1186/s12885-020-07186-5.

299. Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T, Komatsu Y, Yuki S, Wakabayashi M, Nomura S, Sato A, Kuwata T, Kawazu M, Mano H, Togashi Y, Nishikawa H, **Yoshino T**. Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial). ***Clin Cancer Res.*** 2020 Jul 21:clincanres.1803.2020. doi: 10.1158/1078-0432.CCR-20-1803. Online ahead of print. **(Corresponding author)**

300. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, **Yoshino T**, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. ***N Engl J Med.*** 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. PMID: 33264544.

301. Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii A, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, **Yoshino T**, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J. Phase Ib/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). ***Oncologist.*** 2020 Jul 14. doi: 10.1634/theoncologist.2020-0643. Online ahead of print.

302. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, **Yoshino T**. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. ***Nat Med. 2020*** Oct 5. doi: 10.1038/s41591-020-1063-5. Online ahead of print. **(Corresponding author)**

303. Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, Laurent-Puig P, Quirke P, **Yoshino T**, Taieb J, Martinelli E, Arnold D; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ***Ann Oncol.*** 2020 Oct;31(10):1291-1305. doi: 10.1016/j.annonc.2020.06.022. Epub 2020 Jul 20. PMID: 32702383.

304. Ishii T, Kawazoe A, Sasaki A, Mishima S, Kentaro S, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, **Yoshino T**, Kuwata T, Ishii G, Shitara K. Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. ***Ther Adv Med Oncol.*** 2020 Jul 17;12:1758835920942377. doi: 10.1177/1758835920942377. PMID: 32733607; PMCID: PMC7370559.

305. Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Maeda F, Komeno C, Sonezaki T, Takeuchi M, Fujii M, **Yoshino T**, Ichikawa W, Tsuji A. *RAS* mutations in circulating tumor DNA and clinical outcomes of re-challenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer. ***JCO Precision Oncology*** 2020 July 28, 2020: DOI https://doi.org/10.1200/PO.20.00109

306. Sasaki A, Harano K, Kogawa T, Matsubara N, Naito Y, Hosono A, Mukai H, **Yoshino T**, Mukohara T. Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer. ***Case Rep Oncol Med.*** 2020 Jun 16;2020:7231358. doi: 10.1155/2020/7231358. PMID: 32612862; PMCID: PMC7317333.

307. Kobayashi S, Takahashi S, **Yoshino T**, Taniguchi H. ASO Author Reflections: The Moment that BRAF V600E Mutation Start to Evolve into 'Precision Onco-surgery' in Colorectal Liver Metastases. ***Ann Surg Oncol.*** 2020 Jul 8. doi:

10.1245/s10434-020-08818-7. Online ahead of print.

308. Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, **Yoshino T**, Akimoto T, Shitara K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ***ESMO Open.*** 2020 Jul;4(Suppl 2):e000775. doi: 10.1136/esmoopen-2020-000775. PMID: 32719002; PMCID: PMC7381840.

309. Kobayashi S, Takahashi S, Takahashi N, Masuishi T, Shoji H, Shinozaki E, Yamaguchi T, Kojima M, Gotohda N, Nomura S, **Yoshino T**, Taniguchi H. Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. ***Ann Surg Oncol.*** 2020 Jul 13. doi: 10.1245/s10434-020-08817-8. Online ahead of print.

310. **Yoshino T**, Lenz HJ. Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Giuseppe et al. ***Ann Oncol.*** 2020 Apr 30. pii: S0923-7534(20)39311-X. doi: 10.1016/j.annonc.2020.04.012. [Epub ahead of print] (**First and Corresponding author**)

311. **Yoshino T**, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. ***Ann Oncol.*** 2020 Apr 6. pii: S0923-7534(20)36386-9. doi: 10.1016/j.annonc.2020.03.299. [Epub ahead of print] (**First and Corresponding author**)

312. Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, **Yoshino T**, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of The Change of Outcomes Over A Ten-Year Period in Patients With Stage III Colon Cancer: Pooled Analysis of 6,501 Patients Treated with Fluorouracil, Leucovorin and Oxaliplatin in ACCENT Database. ***Ann Oncol.*** 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16.

313. Kawazoe A, Kuboki Y, Bando H, Fukuoka S, Kojima T, Naito Y, Iino S, Yodo Y, Doi T, Shitara K, **Yoshino T**. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. ***Cancer Chemother Pharmacol.*** 2020 Mar 31. doi: 10.1007/s00280-020-04059-3. [Epub ahead of print] (**Corresponding author**)

314. Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A,

Kuboki Y, Taniguchi H, Kojima T, Doi T, **Yoshino T**, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K. Enhanced Tumor Response to Radiotherapy after PD-1 Blockade in Metastatic Gastric Cancer. ***Gastric Cancer***. 2020 Mar 16. doi: 10.1007/s10120-020-01058-4. [Epub ahead of print]

315. Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, **Yoshino T**, Ishii G, Kuwata T, Shitara K. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. ***Clin Cancer Res.*** 2020 Mar 10. pii: clincanres.0075.2020. doi: 10.1158/1078-0432.CCR-20-0075. [Epub ahead of print]
316. Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, **Yoshino T**, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. ***Ann Oncol.*** 2020 Jan 16. pii: S0923-7534(20)35929-9. doi: 10.1016/j.annonc.2020.01.008. [Epub ahead of print]
317. Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, **Yoshino T**, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. ***Ann Oncol.*** 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20.
318. Grothey A, Blay JY, Pavlakis N, **Yoshino T**, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. ***Cancer Treat Rev.*** 2020 *F*eb 20;86:101993. doi: 10.1016/j.ctrv.2020.101993. [Epub ahead of print] Review.
319. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, **Yoshino T**, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. ***Clin Cancer Res.*** 2020 Feb 11. pii: clincanres.3579.2019. doi: 10.1158/1078-0432.CCR-19-3579. [Epub ahead of print]
320. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B,

Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, **Yoshino T**, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group. Guidelines for time-to-event endpoint definitions in adjuvant randomized trials for localized colon cancer patients: results of the DATECAN initiative. ***Eur J Cancer.*** 2020 Mar 12;130:63-71. doi: 10.1016/j.ejca.2020.02.009. [Epub ahead of print]

321. Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, Nakamura Y, Kopetz S, Park WY, Tsuchihara K, Kim TW, Raghav K, **Yoshino T**. International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. ***JCO Precision Oncology*** no. 4(2020)6-19. Published online January 7, 2020
322. Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, **Yoshino T**. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ***ESMO Open.*** 2020;5(1):e000624. doi: 10.1136/esmoopen-2019-000624. Epub 2020 Sep 30. PMID: 33551068.
323. Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Peters S, **Yoshino T**, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. ***Ann Oncol. 2020*** Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.
324. **Yoshino T**, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ***Ann Oncol. 2020*** Jan;31(1):88-95. doi:

10.1016/j.annonc.2019.10.005. (**First and Corresponding author**)

325. Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, **Yoshino T**, Taniguchi H. Japan Society of Clinical Oncology/Japanese Society of Medical Oncology-Led Clinical Recommendations on the Diagnosis and Use of Tropomyosin Receptor Kinase Inhibitors in Adult and Pediatric Patients with Neurotrophic Receptor Tyrosine Kinase Fusion-Positive Advanced Solid Tumors, Cooperated by The Japanese Society of Pediatric Hematology/Oncology. ***Int J Clin Oncol.*** 2020 Jan 24. doi: 10.1007/s10147-019-01610-y. [Epub ahead of print]

326. Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, Bando H, Taniguchi H, Shitara K, Kojima T, Tsuji A, **Yoshino T**. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy in patients with metastatic colorectal cancer. ***BMC Cancer.*** 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6.

327. Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, **Yoshino T**, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Relationship between the immune microenvironment of different locations in a primary tumor and clinical outcomes of esophageal squamous cell carcinoma. ***Br J Cancer*** 2019 Nov 25. doi: 10.1038/s41416-019-0622-3. [Epub ahead of print]

328. Hosono Y, Masuishi T, Yamaguchi R, Kato S, **Yoshino T**, Ebi H. Evaluation of ALK fusion newly identified in colon cancer by a comprehensive genomic analysis. ***JCO Precision Oncology*** - published online November 1, 2019

329. Demachi K, Bando H, Nomura H, Shitara K, **Yoshino T**, Yamaguchi M, Kawasaki T. Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: A single institutional study. ***Jpn J Clin Oncol.*** 2019 Nov 6. pii: hyz157. doi: 10.1093/jjco/hyz157. [Epub ahead of print]

330. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, **Yoshino T**, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II, Open-Label, Study of Pembrolizumab in Treatment Refractory, Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: KEYNOTE-164. ***J Clin Oncol.*** 2019 Nov 14:JCO1902107. doi:

10.1200/JCO.19.02107. [Epub ahead of print]

331. Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, **Yoshino T**. Rationale and design of the BRAVERY study (EPOC1701): A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ***ESMO Open.*** 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

332. **Yoshino T**, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. ***Cancer Chemother Pharmacol.*** 2019 Dec;84(6):1269-1277. doi: 10.1007/s00280-019-03957-5. Epub 2019 Sep 23. (**First and corresponding author**)

333. Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, **Yoshino T**. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. ***Cancer Sci.*** 2019 Sep 14. doi: 10.1111/cas.14198. [Epub ahead of print] (**Corresponding author**)

334. Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, **Yoshino T**. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. ***Jpn J Clin Oncol.*** 2019 Oct 28. pii: hyz149. doi: 10.1093/jjco/hyz149. [Epub ahead of print]

335. Lenz HJ, Argiles G, **Yoshino T**, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. ***Clin Colorectal Cancer.*** 2019 Sep 4. pii: S1533-0028(18)30525-5. doi: 10.1016/j.clcc.2019.08.005. [Epub ahead of print]

336. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, **Yoshino T**, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF

V600E-Mutated Colorectal Cancer. ***N Engl J Med.*** 2019 Sep 30. doi: 10.1056/NEJMoa1908075. [Epub ahead of print]

337. Pietrantonio F, Yaeger R, Schrock AB, Randon G, Romero-Cordoba S, Rossini D, Fucà G, Ross JS, Kotani D, Madison R, Kim ST, Salvatore L, Raimondi A, Pagani F, Borelli B, Perrone F, Bartolomeo MD, Miller VA, Ali SM, Lee J, **Yoshino T**, Braud FD, Falcone A, Hechtman AJF, Cremolini C. Atypical *RAS* mutations in metastatic colorectal cancer. ***JCO Precision Oncology*** - published online September 17, 2019

338. Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, **Yoshino T**, Yao Z, Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. ***Clin Cancer Res.*** 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-2004. [Epub ahead of print]

339. Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, **Yoshino T**, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. ***Clin Cancer Res.*** 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]

340. Fujii S, **Yoshino T**, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Histopathological factors affecting the extraction of high-quality genomic DNA from tissue sections for next-generation sequencing. ***Biomed Rep.*** 2019 Oct;11(4):171-180. doi: 10.3892/br.2019.1235. Epub 2019 Aug 21.

341. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, **Yoshino T**, Yothers G, Sinicrope F, Zaanan A, André T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies. ***Ann Oncol.*** 2019 Jul 3. pii: mdz208. doi: 10.1093/annonc/mdz208. [Epub ahead of print]

342. Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, **Yoshino T**. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA

mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. ***Int J Clin Oncol.*** 2019 Jul 8. doi: 10.1007/s10147-019-01498-8. [Epub ahead of print]

343. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, **Yoshino T**, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. ***Int J Clin Oncol.*** 2019 Jun 15. doi: 10.1007/s10147-019-01485-z. [Epub ahead of print]

344. **Yoshino T**, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 versus 6 Months of Oxaliplatin-based Adjuvant Chemotherapy for Colon Cancer: The Randomized Phase 3 ACHIEVE Trial. ***JAMA Oncology*** 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print] **(First and Corresponding author)**

345. Nakamura Y, Sawada K, Fujii S, **Yoshino T**. HER2-targeted therapy should be shifted toward an earlier line for patients with anti-EGFR-therapy naïve, *HER2*-amplified metastatic colorectal cancer. ***ESMO Open.*** 2019 Jul 8;4(3):e000530. doi: 10.1136/esmoopen-2019-000530. eCollection 2019 **(Corresponding author)**

346. Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, **Yoshino T**. A multicenter, prospective study of plasma circulating tumor DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. ***Br J Cancer*** 2019 Apr 24. doi: 10.1038/s41416-019-0457-y. [Epub ahead of print] **(Corresponding author)**

347. Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, **Yoshino T**, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. ***BMC Cancer.*** 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.

348. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, **Yoshino T**, Wasan H, Desai J, Ciardiello F, Gollerkeri A,

Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients with BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-in Results From the Phase III BEACON Study. ***J Clin Oncol.*** 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459. [Epub ahead of print]

349. Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, **Yoshino T**, Kuwata T, Tsuji A, Shitara K. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. ***J Immunother Cancer. 2019*** Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.
350. Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, **Yoshino T**. Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer. ***Cancer Sci. 2019*** Jan 18. doi: 10.1111/cas.13943. [Epub ahead of print]
351. Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, **Yoshino T**, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogression during nivolumab treatment in patients with advanced gastric cancer. ***Gastric Cancer.*** 2019 Jan 9. doi: 10.1007/s10120-018-00922-8. [Epub ahead of print]
352. Yamaguchi K, Komatsu Y, Satoh T, Uetake H, **Yoshino T**, Nishida T, Yamazaki N, Takikawa H, Morimoto T, Chosa M, Sunaya T, Hamada Y, Muro K, Sugihara K. Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. ***Oncologist.*** 2019 Jan 3. pii: theoncologist.2018-0377. doi: 10.1634/theoncologist.2018-0377. [Epub ahead of print]

353. Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, **Yoshino T**, Prager GW Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. ***Clin Colorectal Cancer. 2018*** Nov 16. pii: S1533-0028(18)30471-7. doi: 10.1016/j.clcc.2018.11.002. [Epub ahead of print] Review.
354. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, **Yoshino T**, Lordick F,

Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. ***Ann Oncol. 2018*** Nov 22. doi: 10.1093/annonc/mdy502. [Epub ahead of print]

355. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, **Yoshino T**, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. ***Ann Oncol. 2018*** Nov 22. doi: 10.1093/annonc/mdy498. [Epub ahead of print]

356. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, **Yoshino T**. REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients. ***Ann Oncol. 2018*** Dec 3. doi: 10.1093/annonc/mdy526. [Epub ahead of print] (**Corresponding author**)

357. Mishima S, **Yoshino T.** MSI Status in Colorectal Cancer. Gan To Kagaku Ryoho. 2018 Nov;45(11):1567-1572. Japanese.

358. Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, **Yoshino T**. Clinical validation of newly developed multiplex kit using Luminex xMAPTM technology for detecting simultaneous *RAS* and *BRAF* mutations in colorectal cancer: Results of the RASKET-B study. ***Neoplasia. 2018*** Dec;20(12):1219-1226. doi: 10.1016/j.neo.2018.10.004. Epub 2018 Nov 6.

359. **Yoshino T,** Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. ***Ann Oncol.*** 2018 Oct 18. doi: 10.1093/annonc/mdy461. [Epub ahead of print] (**First and Corresponding author**)

360. Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu

A, **Yoshino T**, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K. Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ***ESMO Open. 2018*** Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018

361. Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, **Yoshino T**. Utility of the Quasi-monomorphic Variation Range in Unresectable Metastatic Colorectal Cancer Patients. ***Cancer Sci.*** 2018 Aug 24. doi: 10.1111/cas.13774. [Epub ahead of print]
362. **Yoshino T**, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A. Relationship between thymidine kinase 1 expression and trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A pooled analysis of two randomized clinical trials. ***Clin Colorectal Cancer.*** 2018 Jul 26. pii: S1533-0028(18)30261-5. doi: 10.1016/j.clcc.2018.07.009. [Epub ahead of print] (First and Corresponding author)
363. Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, **Yoshino T**, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical Practice Guidance for Next Generation Sequencing in Cancer Diagnosis and Treatment Edition 1.0. ***Cancer Sci.*** 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.
364. **Yoshino T**, Oki E, Nozawa H, Eguchi-Nakajima T, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shirao K. Rationale and design of the TRUSTY Study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ***ESMO Open.*** 2018 Aug 16;3(5):e000411. doi: 10.1136/esmoopen-2018-000411. eCollection 2018 (First and Corresponding author)
365. Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, **Yoshino T**, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. ***Gastric Cancer.*** 2018 Jun 1. doi: 10.1007/s10120-018-0843-9. [Epub ahead of print]

366. Van Cutsem E, **Yoshino T**, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. ***Ann Oncol.*** 2018 Jul 13. doi: 10.1093/annonc/mdy241. [Epub ahead of print]

367. Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, **Yoshino T**, Komatsu Y, Sakamoto N, Okamoto W, Fujii S. Prognostic and Predictive Value of HER2 Amplification in Patients with Metastatic Colorectal Cancer. ***Clin Colorectal Cancer.*** 2018 May 19. pii: S1533-0028(18)30101-4. doi: 10.1016/j.clcc.2018.05.006. [Epub ahead of print]

368. Yamazaki K, Taniguchi H, **Yoshino T**, Akagi K, Ishida H, Ebi H, Nakatani K, Muro K, Yatabe Y, Yamaguchi K, Tsuchihara K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. ***Cancer Sci.*** 2018 Jun;109(6):2074-2079. doi: 10.1111/cas.13617.

369. Naito Y, Takahashi H, Shitara K, Okamoto W, Bando H, Kuwata T, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Watanabe A, Kojima M, Ishii G, Fujii S, Niho S, Ikeda M, Fuse N, Ohno I, Sasaki M, Kohno T, Sato A, Ohtsu A, Ochiai A, **Yoshino T**, Tsuchihara K. Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study. ***Jpn J Clin Oncol.*** 2018 Jun 1;48(6):559-564

370. Kotaka M, Yamanaka T, **Yoshino T**, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ***ESMO Open***. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018 **(Corresponding author)**

371. Grothey A, Sobrero AF, Shields AF, **Yoshino T**, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. ***N Engl J Med.*** 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

372. Shinozaki E, **Yoshino T**, Tsuchihara K. Reply to comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal

antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study". ***Br J Cancer.*** 2018 Mar 22. doi: 10.1038/s41416-018-0040-y. [Epub ahead of print] **(Corresponding author)**

373. Grothey A, **Yoshino T**, Bodoky G, Ciuleanu T, Garcia-Carbonero R, García-Alfonso P, Van Cutsem E, Muro K, Mytelka DS, Li L, Lipkovich O, Hsu Y, Sashegyi A, Ferry D, Nasroulah F, Tabernero J. Association of Baseline Absolute Neutrophil Counts and Survival in Patients with Metastatic Colorectal Cancer Treated with Second-Line Anti-Angiogenic Therapies: Exploratory Analyses of the RAISE Trial and Validation in an Electronic Medical Record Dataset. ***ESMO Open.*** 2018 Apr 24;3(3):e000347. doi: 10.1136/esmoopen-2018-000347. eCollection 2018.

374. Nakamura Y, **Yoshino T**. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. ***Oncologist.*** Oncologist. 2018 Apr 26. pii: theoncologist.2017-0621. doi: 10.1634/theoncologist.2017-0621. [Epub ahead of print] Review. **(Corresponding author)**

375. Sobrero A, Grothey A, Iveson T, Labianca R, **Yoshino T**, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A. The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer? ***Ann Oncol.*** 2018 Feb 9. doi: 10.1093/annonc/mdy064. [Epub ahead of print]

376. **Yoshino T**, Hsu Y, Nasroulah F. Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al. ***Eur J Cancer.*** 2018 Feb 9. pii: S0959-8049(18)30084-4. doi: 10.1016/j.ejca.2018.01.070. [Epub ahead of print]

377. Oki E, Kato T, Bando H, **Yoshino T**, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. ***Clinical Colorectal Cancer*** 2018 Feb 9. pii: S1533-0028(17)30313-4. doi: 10.1016/j.clcc.2018.01.011. [Epub ahead of print]

378. Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, **Yoshino T**, Doi T, Shitara K. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. ***BMC Cancer*** 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.

379. Corcoran RB, Andre T, Atreya CE, Schellens JHM, **Yoshino T**, Bendell JC,

Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer. ***Cancer Discov.*** 2018 Feb 5. pii: CD-17-1226. doi: 10.1158/2159-8290.CD-17-1226. [Epub ahead of print]

380. Jonker DJ, Nott L, **Yoshino T**, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. ***Lancet Gastroenterol Hepatol.*** 2018 Jan 31. pii: S2468-1253(18)30009-8. doi: 10.1016/S2468-1253(18)30009-8. [Epub ahead of print]

381. Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, Shimodaira H, Sekine S, Tanaka T, Chino A, Tomita N, Nakajima T, Hasegawa H, Hinoi T, Hirasawa A, Miyakura Y, Murakami Y, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, **Yoshino T,** Boku N, Fujimori T, Itabashi M, Kinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Sugihara K, Watanabe T, Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version). ***J Anus Rectum Colon.*** 2018 May 25;2(Suppl I):S1-S51. doi: 10.23922/jarc.2017-028. eCollection 2018. Review.

382. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, **Yoshino T**, Voon DC, Yano S, Ebi H. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. ***Oncogene***. 2018 Jan 19. doi: 10.1038/s41388-017-0035-9. [Epub ahead of print]

383. **Yoshino T**, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. ***Ann Oncol. 2018*** Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738. (**First and Corresponding author**)

384. Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, **Yoshino T**. Integrated safety summary for trifluridine/tipiracil (TAS-102). ***Anticancer Drugs***. 2017 Nov 24. doi: 10.1097/CAD.0000000000000554. [Epub ahead of print]

385. Tabernero J, Hozak RR, **Yoshino T**, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E. Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study. ***Ann Oncol***. 2017 Dec 7. doi: 10.1093/annonc/mdx767. [Epub ahead of print]

386. Tanase T, Hamada C, **Yoshino T**, Ohtsu A. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. ***Anticancer Res.*** 2017 Oct;37(10):5851-5855.

387. E. Van Cutsem, A. Falcone, R. Garcia - Carbonero, Y. Komatsu, A. Pastorino, M. Peeters, Y. Shimada, K. Yamazaki, **T. Yoshino**, A. Zaniboni, N. Amellal, A. Kanehisha, Robert Winkler, L. Makris, R. J. Mayer, A. Ohtsu, J. Tabernero. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ***ESMO Open*** 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017.

388. Shinozaki E, **Yoshino T**, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. ***Br J Cancer. 2017*** Oct 3. doi: 10.1038/bjc.2017.308. [Epub ahead of print] (**Co-first and Corresponding author**)

389. Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, **Yoshino T**, Ochiai A. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma. ***J Cancer Res Clin Oncol.*** 2017 Jul 29. doi: 10.1007/s00432-017-2482-7. [Epub ahead of print]

390. Cohn AL, **Yoshino T**, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D,

Nasroulah F, Tabernero J. Exposure-Response Relationship of Ramucirumab in Patients with Advanced Second-Line Colorectal Cancer: Exploratory Analysis of the RAISE trial. ***Cancer Chemother Pharmacol***. 2017 Jul 25. doi: 10.1007/s00280-017-3380-z. [Epub ahead of print]

391. Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, **Yoshino T**, Ushijima T. Targeting of super-enhancers and mutant BRAF can suppress growth of *BRAF*-mutant colon cancer cells via repression of MAPK signaling pathway. ***Cancer Letters*** 2017 Aug 28;402:100-109. doi: 10.1016/j.canlet.2017.05.017. Epub 2017 May 31.
392. Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Shogo Nomura S, Doi T, Sato A, Ohtsu A, **Yoshino T**. A multicenter phase 1/2 study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). ***Lancet Oncol.*** 2017 Jul 28. pii: S1470-2045(17)30425-4. doi: 10.1016/S1470-2045(17)30425-4. [Epub ahead of print] (**Corresponding author**)
393. Arnold D, Fuchs C, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Paz-Ares L, Baron A, Okusaka IT, **Yoshino T**, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. ***Ann Oncol***. 2017 Sep 7. doi: 10.1093/annonc/mdx514. [Epub ahead of print]
394. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, **Yoshino T**, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. ***Int J Clin Oncol.*** 2017 Mar 27. doi: 10.1007/s10147-017-1101-6. [Epub ahead of print]
395. **Yoshino T**, Obermannová R, Bodoky G, Garcia-Carbonero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Tabernero J. Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase 3 Trial. ***Eur J Cancer.*** 2017 Jun;78:61-69. doi: 10.1016/j.ejca.2017.03.007. Epub 2017 Apr 13.
396. Taniguchi H, Iwasa S, Yamazaki K, **Yoshino T**, Kiryu C, Naka Y, Liew E, Sakata Y.

Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. ***Cancer Science*** 2017 May;108(5):1013-1021. doi: 10.1111/cas.13227. Epub 2017 May 11

397. **Yoshino T**, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Iwasaki K, Soeda J, Hihara M, Yamanaka T, Ochiai A, Muro K. Rationale for and Design of the PARADIGM study: Randomized Phase III Study of mFOLFOX6 plus Bevacizumab or Panitumumab in Chemotherapy-Naïve Patients with RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. ***Clin Colorectal Cancer.*** 2017 Jun;16(2):158-163. doi: 10.1016/j.clcc.2017.01.001. Epub 2017 Jan 24

398. van Geel RM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, **Yoshino T**, Delord JP, Yamada Y, Lolkema M, Faris JE, Eskens FA, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JH. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. ***Cancer Discov***. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

399. Hatogai K, Fujii S, Kojima T, Daiko H, Doi T, Ohtsu A, Ochiai A, Takiguchi Y, **Yoshino T**. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. ***BMC Cancer*** 2017 DOI 10.1186/s12885-016-3041-3 [Epub ahead of print]

400. Doi T, Fuse N, **Yoshino T**, Kojima T, Bando H, Miyamoto H, Kaneko M, Osada M, Ohtsu A. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. ***Cancer Chemother Pharmacol.*** 2017 Jan;79(1):89-98. doi: 10.1007/s00280-016-3198-0.

401. **Yoshino T**, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N. Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. ***Cancer Chemother Pharmacol.*** 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. (**Corresponding author**)

402. Doi A, Kuboki Y, Shitara K, Fukuoka S, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, **Yoshino T**. Gastrointestinal perforation and fistula formation in five cases with colorectal cancer during treatment with regorafenib. ***Clin Colorectal Cancer.*** 2016 Dec 28. pii: S1533-0028(16)30257-2. doi: 10.1016/j.clcc.2016.11.003. [Epub ahead of print]

403. Nagatani Y, Shitara K, Bando H, Kuboki Y, Okamoto W, Kojima T, **Yoshino T**,

Nishida T, Ohtsu A, Doi T. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. ***BMC Cancer.*** 2016 Nov 14;16(1):889

404. Ushijima T, **Yoshino T**. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. ***Cancer Res.*** November 15, 2016 76:6443-6444; doi:10.1158/0008-5472.CAN-16-2867
405. Kotani D, Kuboki Y and **Yoshino T**. Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan. ***Curr Colorectal Cancer Rep***. 2016 DOI 10.1007/s11888-016-0336-3 s Review. (**Corresponding author**)
406. Obermannová R, Van Cutsem E, **Yoshino T**, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J. Subgroup analysis in RAISE: A randomized, double-blind phase 3 study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. ***Ann Oncol.*** 2016 Nov;27(11):2082-2090.
407. Bando H, Rubinstein L, Harris P, **Yoshino T**, Doi T, Ohtsu A, Welch J, Takebe N. Analysis of Esophago-Gastric Cancer Patients Enrolled in the National Cancer Institute –Cancer Therapy Evaluation Program -Sponsored Phase 1Trials. ***Gastric Cancer***. 2016 Aug 10. [Epub ahead of print]
408. Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, **Yoshino T**, Doi T, Ohtsu A, Ochiai A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. ***Gastric Cancer***. 2016 Sep 14. [Epub ahead of print]
409. Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, **Yoshino T**. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. ***Clin Colorectal Cancer.*** 2016 Aug 18. pii: S1533-0028(16)30119-0. doi: 10.1016/j.clcc.2016.07.012.
410. Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A and **Yoshino T**. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. ***BMC Cancer*** 2016 July 16:467 doi: 10.1186/s12885-016-2491-y
411. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A,

Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, **Yoshino T**, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. ***Ann Oncol***. 2016 Jul 5. pii: mdw235. [Epub ahead of print] Review.

412. Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, **Yoshino T**, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma ***Oncotarget.*** 2016 Jul 26;7(30):47252-47264. doi: 10.18632/oncotarget.10055.

413. Yamanaka T, Oki E, Yamazaki K, Yamaguchi K, Muro K, Uetake H, Sato T, Nishina T, Ikeda M, Kato T, Kanazawa A, Kusumoto T, Chao C, Lopatin M, Krishnakumar J, Bailey H, Akagi K, Ochiai A, Ohtsu A, Ohashi Y, **Yoshino T**. The 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer with Surgery Alone: SUNRISE Study. ***J Clin Oncol***. 2016 Jun 20. pii: JCO670414. [Epub ahead of print] **(Corresponding author)**

414. **Yoshino T**, Uetake H, Fujita N, Furuta T, Katori J, Hara N, Muro K. TAS-102 Safety in Metastatic Colorectal Cancer: Results from the First Post-marketing Surveillance Study. ***Clin Colorectal Cancer.*** 2016 May 17. pii: S1533-0028(16)30052-4. doi: 10.1016/j.clcc.2016.04.004. [Epub ahead of print] **(Corresponding author)**

415. Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, **Yoshino T.** A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients. ***Cancer Sci***. 2016 Mar 17. doi: 10.1111/cas.12932. [Epub ahead of print]

416. Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, **Yoshino T**, Ohtsu A, Watanabe T, Matsuda F. Large-Scale Prospective Pharmacogenomics Study of Oxaliplatin-Induced Neuropathy in Colon Cancer Patients enrolled in the JFMC41-1001-C2 (JOIN Trial). ***Ann Oncol.*** 2016 Feb 18. pii: mdw074. [Epub ahead of print]

417. **Yoshino T**, Kojima T, Bando H, Yamazaki T, Naito Y, Mukai H, Fuse N, Goto, K, Ito Yuko, Doi T, Ohtsu A. The Effect of Food on the Pharmacokinetics of TAS-102 and its Efficacy and Safety in Patients with Advanced Solid Tumors. ***Cancer Sci.*** 2016

Feb 26. doi: 10.1111/cas.12912. [Epub ahead of print] (**Corresponding author**)

418. Osera S, Fujii S, Ikematsu H, Miyamoto H, Oono Y, Yano T, Ochiai A, **Yoshino T**, Ohtsu A, Kaneko K. Clinicopathological, endoscopic, and molecular characteristics of the "skirt" - a new entity of lesions at the margin of laterally spreading tumors. ***Endoscopy***. 2016 Jan 25. [Epub ahead of print]

419. Doi T, Shitara K, Kojima T, **Yoshino T**, Dontabhaktuni A, Rebscher H, Tang S, Cosaert J, Ohtsu A. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. ***Cancer Chemother Pharmacol.*** 2016 Jun;77(6):1253-62. doi: 10.1007/s00280-016-3041-7. Epub 2016 Apr 30.

420. Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, **Yoshino T**, Doi T, Takiguchi Y, Ohtsu A. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. ***J Surg Oncol.*** 2016 Mar;113(4):390-6. doi: 10.1002/jso.24151. Epub 2016 Jan 12.

421. Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, **Yoshino T**. Safety and efficacy of TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer: experience at a single institution. ***Clinical Colorectal Cancer*** 2015 Nov 27. pii: S1533-0028(15)00150-4. doi: 10.1016/j.clcc.2015.11.005. [Epub ahead of print]

422. Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, **Yoshino T,** Doi T, Ochiai A, Ohtsu A. Comprehensive Analyses Using Next-Generation Sequencing and Immunohistochemistry Enable Precise Treatment in Advanced Gastric Cancer. ***Ann Oncol.*** 2015 Oct 21. pii: mdv508. Epub ahead of print

423. Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, **Yoshino T**, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada JI, Sakamoto H, Yoshida T. Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. ***BMC Cancer.*** 2015 Oct 16;15(1):718.

424. Van Cutsem E, **Yoshino T**, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J.E. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment ***Clinical Colorectal Cancer*** 2015 Oct 9. pii:

S1533-0028(15)00115-2. doi: 10.1016/j.clcc.2015.09.005. Epub ahead of print

425. Doi T, **Yoshino T**, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. ***Anti-Cancer Drugs.*** 2015 Aug 18. Epub ahead of print

426. Doi T, **Yoshino T,** Fuse N, Boku N, Yamazaki K, Koizumi W, Shimada K, Takinishi Y, Ohtsu A. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. ***Invest New Drugs.*** 2015 Jul 12. Epub ahead of print.

427. Nishina T, Kato T, Yamazaki K, **Yoshino T**, Miyata Y, Esaki T, Moriwaki T, Boku N, Hyodo I. Phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. ***Cancer Chemother Pharmacol.*** 2015 Jul 22. Epub ahead of print

428. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, **Yoshino T**, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. ***Lancet Oncol***. 2015 Jul 13. pii: S1470-2045(15)00138-2. doi: 10.1016/S1470-2045(15)00138-2. Epub ahead of print.

429. **Yoshino T**, Yamazaki K, Gotoh M, Nasroulah F, Gao L, Yoshizuka N, Ohtsu A. Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. ***Anticancer Res***. 2015 Jul;35(7):4003-7. **(Corresponding author)**

430. Hecht JR, Mitchell EP, **Yoshino T**, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. ***Cancer Manag Res.*** 2015 Jun 15;7:165-73. doi: 10.2147/CMAR.S61408. eCollection 2015.

431. Doi T, Tamura K, Tanabe Y, Yonemori K, **Yoshino T**, Fuse N, Kodaira M, Bando H, Noguchi K, Shimamoto T, Ohtsu A. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors. ***Cancer Chemother Pharmacol.*** 2015 Jun 24. [Epub ahead of print]

432. Kotaka M, **Yoshino T**, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy

in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). *Cancer Chemother Pharmacol.* 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16. (**Corresponding author**)

433. Mayer RJ, Van Cutsem E, Falcone A, **Yoshino T**, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med.* 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.

434. Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, **Yoshino T.** A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. *BMC Cancer.* 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z. (**Corresponding author**)

435. Tabernero J, **Yoshino T**, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol.* 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.

436. Yoshida M, Muro K, Tsuji A, Hamamoto Y, **Yoshino T**, Yoshida K, Shirao K, Miyata Y, Takahari D, Takahashi T, Ohtsu A. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). *Eur J Cancer.* 2015 May;51(8):935-41. doi: 10.1016/j.ejca.2015.03.007. Epub 2015 Mar 30.

437. **Yoshino T**, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, Okamoto W, Taniguchi H, Akagi K, Kajiwara T, Hironaka S, Satoh T.Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. *EBioMedicine.* 2015 Feb 14;2(4):317-23. doi: 10.1016/j.ebiom.2015.02.007. eCollection 2015 Apr. (**Corresponding author**)

438. Hashimoto Y, **Yoshino T.** Chemotherapeutic agents and electrolyte imbalance]. *Nihon Rinsho.* 2015 Feb;73 Suppl 2:426-31. (**Corresponding author**)

439. Taniguchi H, Yamazaki K, **Yoshino T,** Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K; Japanese Society of Medical Oncology. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. ***Cancer Sci.*** 2015 Mar;106(3):324-7. doi: 10.1111/cas.12595.

440. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, **Yoshino T**, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. ***Int J Clin Oncol.*** 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18.

441. Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, **Yoshino T,** Ohtsu A, Doi T. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. ***Invest New Drugs.*** 2015 Jun;33(3):664-70. doi: 10.1007/s10637-015-0231-9. Epub 2015 Mar 15.

442. Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, **Yoshino T,** Ochiai A, Ohtsu A. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. ***Gastric Cancer.*** 2015 Feb 15. [Epub ahead of print]

443. Kotani D, Fukuoka S, **Yoshino T.** Efficacy of TAS-102. ***Gan To Kagaku Ryoho.*** 2015 Jan;42(1):1-5. Review. Japanese. **(Corresponding author)**

444. Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, **Yoshino T**, Asano H, Ochiai A, Komatsu Y, Sakamoto N, Ohtsu A. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. ***Jpn J Clin Oncol.*** 2015 Jan;45(1):43-8. doi: 10.1093/jjco/hyu174. Epub 2014 Nov 6.

445. **Yoshino T**, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. ***Invest New Drugs.*** 2015 Jun;33(3):740-50. doi: 10.1007/s10637-014-0154-x. Epub 2014 Sep 12. **(Corresponding author)**

446. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, **Yoshino T,** Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G,

Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. ***Gut.*** 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

447. **Yoshino T**, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ***Invest New Drugs***. 2013;31(4):910-7. **(Corresponding author)**
448. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, **Yoshino T**, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. ***Lancet.*** 2013;381(9863):303-12.
449. Bando H, **Yoshino T**, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. ***BMC cancer***. 2013;13(1):405. **(Corresponding author)**
450. Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, **Yoshino T,** Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. ***Current colorectal cancer reports.*** 2013;9:261-9.
451. **Yoshino T**, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. ***Lancet Oncol***. 2012;13(10):993-1001. **(Corresponding author)**
452. Kawamoto Y, Tsuchihara K, **Yoshino T**, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of

colorectal cancer. ***Br J Cancer.*** 2012;107:340-4.

453. Doi T, Ohtsu A, **Yoshino T,** Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. ***Br J Cancer.*** 2012;107(3):429-34.

454. Bando H, **Yoshino T**, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. ***Jpn J Clin Oncol.*** 2012;42(12):1146-51. (**Corresponding author**)

455. Bando H, **Yoshino T**, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. ***Br J Cancer.*** 2011;105(3):403-6. (**Corresponding author**)